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INTRODUCTION  
We review point-of-care (POC) diagnostics, in-
vitro diagnostic (IVD) tests that do not involve the 
use of laboratory staff and facilities to provide the 
result.  The analytical “targets” include proteins, 
nucleic acids, metabolites, drugs, dissolved ions and 
gases, human cells, and invading microbes.  Sam-
ples are blood, saliva, urine, or other bodily fluids 
or (semi)solids.  Whether used “near-patient” in a 
hospital, clinic, or doctor’s office, or administered 
at home to maintain health, manage disease, or 
monitor therapy, or in the field to test the safety of 
water, food, or compliance with laws and regula-
tions, these tests accept a sample with little or no 
pre-preparation and provide a result—the “an-
swer”—in seconds to hours.1  The tests require only 
elementary instruction to use and some detect mul-
tiple analytes or markers.2  Interpretation may be as 
simple as viewing a stripe or spot of color on a strip 
of paper or polymer; increasingly, however, readers 
ranging from hand-held devices to benchtop instru-
ments read the analytical test, provide a comprehen-
sible result and, if necessary, control and operate the 
sample-containing platform that executes the ana-
lytical process. 
An idealized concept of a POC device is shown 
in Figure 1.  These devices are challenged by small 
sample volumes (100s of nL to ~ 1 mL) of complex 
biological media with fM – mM concentrations of 
analytes.3  The devices should be inexpensive dis-
posable chips or cartridges that include microfluidic 
features to provide or control sample preparation, 
flow rate, mixing with reagents, reaction time asso-
ciated with binding events, filtration of non-
analytical components of the sample, separation of 
interferents and of multiple analytes, and an effec-
tive measurement capability.4 
POC diagnostics have been extensively re-
viewed in recent years, from the points of view of 
both use5 and development.6  The reviews have in-
cluded coverage of micro-total analysis systems 
(!TAS),7 miniaturized isothermal nucleic acid am-
plification8 and molecular biological techniques for 
gene assay,9 current and anticipated technology for 
POC infection diagnosis,10 and microfluidic-based 
systems leading toward point-of-care detection of 
nucleic acids and proteins,11 including multiplexing 
and label-free methods.12  Developments in this area 
include not only technology but also reliable meas-
urement targets, which in some important areas re-
main elusive: progress toward viable point-of-care 
protein biomarker measurements for cancer detec-
tion and diagnostics has been reviewed.13 
We review here the present status of POC diag-
nostics, emphasizing in particular the past 4 years, 
then extrapolate their progress into the future.  In-
cluded are IVD tests for biochemical targets of all 
sorts relevant to human health, diagnosis, and ther-
apy, as enumerated above.  We begin by overview-
ing the different classes of bioanalytical targets.  
Then, after setting the context using the well-
established glucose and pregnancy POC tests, re-
cent progress in key enabling technologies is re-
viewed, including traditional and advanced lateral 
flow approaches, printing and laminating technolo-
gies, a range of microfluidic advances, progress in 
surface chemistry and the control of non-specific 
binding, and developments in labeled and label-free 
detection approaches.  A number of specific innova-
tive examples, in both commercial products and 
academic POC research, are presented, including 
assays based on binding to proteins, nucleic acids, 
and aptamers, with separate sections devoted to 
blood chemistry, coagulation, and whole cells.  We 
close with trends and future perspectives.   
 
 
 
Figure 1.  Idealized POC device. (Reprinted with 
permission from Gervais et al.6a).  
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Why POC Diagnostics?   
Time. POC measurements provide results rap-
idly, where needed, and often with major time sav-
ings: samples do not travel to a laboratory to await 
the attention of a skilled technician; results do not 
wait to be transmitted and collected.  Rather, the 
doctor, nurse, care-giver, patient, or consumer initi-
ates the test and receives the results on the spot.  
Inevitably this saves time—but speed must not be 
traded for accuracy or reliability.  
 
Patient Responsibility and Compliance.  In pri-
mary care settings, patients are supervised by a 
medical team responsible for administering medica-
tions and monitoring responses.  Although often 
administered by medical professionals, POC tests 
are also widely self-administered, making patients 
far more responsible for managing their own condi-
tion(s).14  Concern over loss of professional control 
and potential for incorrect interpretation of results15 
necessitate management systems to ensure that pa-
tients receive reliable devices and readout training, 
including everything from device maintenance to 
finger-stick sampling procedures, along with gen-
eral information on their medical conditions and 
where to turn for support.16 
In-home POC testing reduces the frequency of 
hospital visits, travel expenses, and lost work 
time.17  The success of glucose meters and preg-
nancy tests has motivated more people to opt for 
self testing,18 conferring increased responsibility to 
maintain their own medical records and notify their 
physicians should abnormal results arise.19  This 
situation can be tenuous, particularly if the patient’s 
mental or physical faculties are compromised.  The 
advent of ‘telemedicine’ or ‘telehealth’14—the pro-
vision of health services over long distances via 
telecommunications—is addressing this challenge 
by giving healthcare professionals partial control 
over patient self-testing and data management.20 
Empowering individuals to do their own tests 
can improve patient compliance (adherence to diag-
nosis and treatment regimens).21  A recent study of 
the cost effectiveness of POC testing reveals sig-
nificant increases in testing regularity and adher-
ence to prescribed medications,22 as well as im-
provements in clinical outcomes.23  Near-patient 
testing in diabetic clinics results in greater patient 
satisfaction, accompanied by better understanding 
of medical results24 and improved long-term prog-
nosis relative to a dearth of testing.21 
POC testing is well established to monitor blood 
coagulation time in conjunction with administration 
of the anticoagulant warfarin: weekly self monitor-
ing of oral anticoagulation coupled with self dosing 
provides more effective anticoagulation therapy 
than conventional testing.25  Similarly, the quality 
of anticoagulation therapy, managed initially in the 
traditional hospital setting then switched to self 
management, deteriorated when patients returned to 
clinical management.26 
 
Cost. POC diagnostic cost parameters differ 
from those of conventional laboratory analysis.  
Readers (instruments) are smaller and more special-
ized than laboratory systems, so they cost less but 
do only one or a few different tests.  Samples do not 
directly contact the reader, hence self-cleaning sub-
systems are not needed.  The POC chip, strip, or 
cartridge—a consumable that contains the sample 
but is not designed for cleaning or re-use—may in-
clude fluidics, on-board reagents and dyes, optics, 
electrodes, even thermal control.  Relative to a 
blood-draw tube, the POC device’s greater com-
plexity and functionality make it more costly, so 
tests sold in large volume derive most of their reve-
nue from the consumable. 
POC tests can indirectly, sometimes drastically, 
lower medical costs: sample mislabeling and mis-
handling, along with misdirection of results, are less 
likely.  Results are provided more quickly, enabling 
more effective treatment of rapidly-progressing af-
flictions, even making a life-or-death difference 
with some infections.  Rapid POC results can obvi-
ate hospital admissions, e.g. when a suspected myo-
cardial infarct is determined rapidly to be indiges-
tion.  On the other hand, sophisticated test car-
tridges cost more than basic sample tubes, and when 
the cost of a large laboratory system can be amor-
tized over hundreds of thousands of samples, cost 
per test can be lower. 
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DIAGNOSTIC TARGETS 
Proteins 
Proteins, including enzymes, antibodies, and 
some hormones, are common targets for POC diag-
nostics.  An early POC device developed in 1957, 
the urinalysis dipstick measures urinary protein us-
ing paper strips impregnated with a pH indicator 
dye.27  Diabetics and kidney-disease patients were 
enabled to test their urine at home, providing a pre-
viously unrealizable degree of feedback to manage 
their own health.  Today, products such as the 
Clinitek Status analyzer by Siemens Healthcare Di-
agnostics allow semi-quantitative electronic readout 
of urine dipsticks. 
Modern POC devices utilize immunoassay tech-
nology, which includes antigen-antibody binding, 
whether the antibody is the assay target or the 
means to capture it.  These assays target disease-
specific protein markers such as glycated hemoglo-
bin (HbA1c) for diabetics, C-reactive protein (CRP) 
for inflammation including cardiovascular disease, 
D-dimer for thrombosis, troponin I or T for cardiac 
damage, prostate-specific antigen (PSA) for this 
common cancer, and bacterial and viral infection-
related markers such as human immunodeficiency 
virus (HIV), influenza, chlamydia, and hepatitis.5b  
Commercial POC devices that detect antibodies de-
veloped by the host in response to infection include 
OraQuick© ADVANCE® Rapid Antibody Test for 
HIV, QuickVue© Influenza AB, and Accustrip® 
Strep A for group A streptococcus. 
The best-known home POC protein-detection 
device, the pregnancy test kit measures the preg-
nancy hormone human chorionic gonadotropin 
(hCG).  The test’s key component, the lateral-flow 
test strip, is described in the Lateral Flow Assays 
section. 
 
Metabolites and Other Small Molecules  
Metabolites are products of chemical proc-
esses—metabolism—that generate energy, process 
nutrients or wastes, or break down and renew body 
tissues.28  Because of similarities in their physio-
logical transport and detection approaches for POC 
assays, we treat them here with simple ionic blood 
chemicals (H+, Na+, K+, Cl–, HCO3–, etc.) and 
small-molecule organic species, including non-
protein hormones (e.g. epinephrine, cortisol, and 
peptide hormones).  Levels of metabolites, hor-
mones, and blood-borne chemicals are often diag-
nostic indicators of disease.  The current panel of 
metabolites most often targeted by POC diagnostics 
includes glucose, cholesterol, triglycerides, creatin-
ine, lactate, ammonia, and urea.29  One of the early 
and best-known clinical POC analyzers is the i-
STAT handheld system (Abbott Point of Care, 
Princeton, NJ) for blood chemistry.30 
The best-known metabolite, glucose, enables di-
agnosis and management of diabetes mellitus, an 
endocrine disorder afflicting more than 125 million 
people worldwide;14 glucose biosensors account for 
approximately 85% of the entire biosensor market.31  
Diabetic complications are controllable with tight 
regulation of glucose levels, prompting the devel-
opment of POC glucose sensors in the 1990s.32  
Most diabetic patients now regulate their condition 
at home using handheld glucose meters that analyze 
a small capillary blood sample.5a 
Screening cholesterol,6b triglycerides, and other 
plasma lipids is an important component in the 
management of cardiovascular disease, a leading 
cause of mortality worldwide.33  Stroke and diabetes 
are also linked to high cholesterol, bolstering its 
importance as a POC diagnostic target. 
Creatinine, a by-product of kidney function, is 
produced at a constant rate in healthy individuals; 
its level is diagnostic for defective renal function 
through estimation of the glomerular filtration 
rate.34  Lactate measurements are often performed 
in the emergency room to provide valuable informa-
tion about tissue perfusion and the presence of 
ischemia or hypoxia:35 elevated lactate often sug-
gests inadequate blood oxygenation. 
Renal dysfunction, liver disease, and asthma can 
often be detected through the measurement of urea 
and ammonia levels;36 high bloodstream ammonia 
levels are related to slow conversion to urea due to 
liver impairment.37  Uremia or kidney failure can 
lead to high levels of breath ammonia,38 which is 
well suited to non-invasive breath-test-based POC 
diagnostics.39 
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Other metabolites of interest include those pro-
duced as a result of recreational drug use or illegal 
substance abuse.  The effects of nicotine are well 
known, with an astounding 4.9 million deaths per 
annum; self testing for nicotine metabolites was 
suggested by Barnfather et al. as a motivational fac-
tor in smoking cessation.40  POC diagnostics are 
very popular for the detection of the metabolites of 
illegal drugs such as cocaine, opiates, and cannabis 
in workplace or prison settings.41 
 
Nucleic Acids 
Nucleic acid diagnostics, often referred to as 
‘molecular diagnostics’ (in seeming oblivion to the 
molecular nature of proteins and metabolites), 
measure DNA or various types of RNA in order to 
assay particular genomic or genetic details of a pa-
tient, or to assay nucleic acid sequences unique to 
invading pathogens.  PCR (polymerase chain reac-
tion) and numerous other methods of selectively 
copying (“amplifying”) pre-selected nucleic acid 
sequences are often part of such assays, rendering 
them at once exceptionally sensitive (to a few cop-
ies of the target sequence), highly selective (only 
predefined target sequences are amplified), but also 
more expensive, cumbersome, and time-consuming 
than other POC assays. 
In POC diagnostics devices, sample volumes are 
often measured in microliters, and little or no user 
manipulation should be necessary.  Assay design is 
therefore more challenging than standard DNA mi-
croarray-based assays,42 and ideally involves just 
two specific binding events once any sample pre-
processing has occurred: target nucleic acid from 
the sample is specifically captured on a substrate 
surface, usually through hybridization with a com-
plementary, surface-bound “probe” DNA, and the 
captured target is then detected through a second 
hybridization event between its free end and a com-
plementary, labeled oligonucleotide (normally 
short, 10 – 15 bases) (Figure 2).  Measurement sen-
sitivity is often controlled by the hybridization effi-
ciency of both events and by the level of back-
ground signal in the absence of target.  Binding ki-
netics and target specificity can be modulated by 
various factors such as ionic strength, reaction tem-
perature, and probe density.  Recent work has 
shown that low probe densities can lead to higher 
hybridization efficiencies and more rapid binding 
kinetics,43 but at the expense of a smaller measured 
signal that may be more susceptible to background 
interference. 
The time to obtain a test result is a differentiat-
ing factor for nucleic acid tests.  For example, cur-
rent tests for infecting viruses, bacteria, and fungi 
include culturing of organisms44 (not suitable for 
POC testing), various forms of immunoassay,45 and 
nucleic acid testing.46  Culturing microbes requires 
several hours to more than a week, rendering it 
broadly inappropriate for POC testing.  Immunoas-
say is accomplished in minutes to an hour or more 
(depending on incubation times); the time for nu-
cleic acid assay is similar, including demonstrated 
best examples that take only 12 minutes.47 
Direct detection of viruses, bacteria, or fungi by 
POC immunoassay often suffers from inadequate 
LODs, which can be addressed by targeting the 
rRNA molecules present in high copy numbers 
(100s to 1000s) in each cell,48 often with subtyping 
(strain-specific) data as a bonus.  New RNA targets 
have been recently identified as appropriate markers 
for various infectious bacteria, an excellent example 
being tmRNA, present in all bacterial phyla,49 now 
well documented as a molecular diagnostic target.50 
Improvements and new approaches in POC 
technologies will enable multi-parameter assays that 
focus beyond identification of individual microbial 
pathogens to allow multiple antibiotic resistance 
determinations.51  
 
 
 
Figure 2.  Idealized nucleic acid assay: RNA in a 
drop of blood is captured by complementary probe 
strands on the device surface, then labeled by a 2nd 
complementary strand introduced from solution.  
Page 5 of 62
ACS Paragon Plus Environment
Analytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Human Cells  
The identification and enumeration of specific 
human cells (and animal cells for veterinary diag-
nostics) in blood and other samples is a promising 
and rapidly expanding field in POC diagnostics.  In 
addition to basic blood cell counting, it has been 
widely recognized that POC cell-assay-based de-
vices could implement diagnostic and prognostic 
testing for infectious diseases, cancers, inflamma-
tory responses, and hematological parameters,52 and 
this vision is beginning to be realized. 
The assay of cells in POC format is straightfor-
ward in principle: target cells are captured or local-
ized using antibodies, proteins, or aptamers; labeled 
according to the mode of detection; then enumer-
ated.  Presence and numbers of specific receptors on 
cell surfaces can be assayed by selective immuno-
labeling, and interactions with particular solution or 
surface antigens or proteins can be assessed via 
binding; automated counting of cells on device sur-
faces is often straightforward.53 
Whole-cell POC assays will not supplant the 
clinical laboratory flow cytometer, which can fluo-
rescently assay ten or more receptors on each of 
thousands of individual cells per second, also pro-
viding cell morphological information via light scat-
tering.  But these bulky, expensive, complex in-
struments are limited to well-financed central test-
ing laboratories, providing an opportunity for POC 
cell tests to fill a number of specialized niches.  
  
Microbes/Pathogens  
Microbes, viruses, and parasites are an impor-
tant POC analytical target, particularly those that 
cause infectious disease:54 by enabling treatment 
with the proper antimicrobial agent, rapid identifi-
cation of the causative pathogen of a serious infec-
tion can save significant treatment cost, reduce suf-
fering, help stem the spread of disease, and save 
lives.  Because species and strain identification are 
required, pathogens are often diagnosed using nu-
cleic acid identification;8b in some cases they can be 
diagnosed (as in tuberculosis55) via the specific an-
tibodies that are present in an infected host.  None-
theless, a rapid screen to differentiate, for example, 
bacterial from viral infection, or simply to detect a 
pathogen or a piece of it directly, can be an impor-
tant diagnostic step.  In some cases, bacterial assay 
can use antibody capture of whole or fragmented 
organisms, or toxins they produce (as in staphylo-
coccal enterotoxin B56), rather than more complex 
genetic analysis. 
Common POC tests for microbes, or fragments 
thereof, along with their applications and perform-
ance, have been reviewed by Clerc and Greub.54  
For example, group A Streptococcus pyogenes is 
detected by selective binding of its carbohydrate 
antigen; an immunochromatographic (lateral flow) 
assay that detects the C-polysaccharide common to 
the cell walls of all pneumococcal serotypes of 
Streptococcus pneumoniae, approved by the FDA in 
1999, gives a result in 15 min.  The malaria parasite 
is also detected by immunochromatographic assay 
of a particular antigen; each species of the parasite 
has its own assay. 
A laboratory demonstration of immunomagnetic 
pre-concentration/localization and detection of sal-
monella and Staphylococcus aureus using fluores-
cent assay has been reported.57  Viruses have also 
been detected: an influenza rapid POC test sensitive 
to swine lineage A(H1N1) influenza viruses has 
been evaluated.58 
 
Drugs and Food Safety   
Recreational drug abuse and doping in competi-
tive sports are on the rise and constitute significant 
social problems worldwide.  The last decade has 
seen a revolution in the development of tests using 
alternative specimens for drug analysis: tests utiliz-
ing sweat, saliva, and meconium (in infants) have 
been cleared by the US FDA.59  Oral fluid offers 
significant promise when detection of relatively re-
cent use of drugs is sought in a non-invasive man-
ner.60  Technological advances do allow on-site de-
tection of drugs, but there are technical issues in 
relation to collection of oral fluid and in the vari-
ability of drug concentrations in this fluid.  One of 
the successful commercial examples of an on-site 
test for oral fluid drugs of abuse determination is 
Oratect®.  It utilizes a colloidal gold-particle-based 
lateral flow immunoassay and combines sample col-
lection and drug testing in a single device.61 
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Doping has become an issue in elite sport and 
sensitive detection assays that enable the identifica-
tion of small organic compounds on the microscale 
are required.  Sports drug testing approaches can 
utilize paper, thin-layer, or gas chromatography 
methods to reveal the presence of prohibited sub-
stances such as strychnine, pervitine, captagone, or 
benzedrine in doping test specimens.62  Most sport-
doping drugs are also used to treat various diseases 
such as hypertension (beta-blockers), bronchial 
congestion (theophylline), congestive heart failure 
(diuretics), anemia (erythropoietin); many anabolics 
(steroidal hormones), growth hormone, peptides, 
stimulants, and narcotics are legal only when pre-
scribed.  A brief historical overview and the devel-
opment of detection methods for illegal substances 
used in sports, including the very few rapid POC-
like approaches, are interestingly summarized in a 
review by Catlin et al.63 
The challenge in developing drug detection de-
vices is not only short detection times, but also the 
regulation of the tests to assure that they provide the 
right answers.  Existing drug testing methods often 
lack sufficient sensitivity or specificity to the diver-
sified list of drugs of abuse.  As is the case with all 
immunoassays, the probe antibody regulates speci-
ficity.  Due to the similarity of chemical structures 
within drug classes (e.g., opiates), commercially 
available antibodies tend to exhibit high cross-
reactivity in immunoassays.  As a result, immuno-
assay-based devices could provide a practical means 
to analyze high quantities of specimens when the 
majority are expected to test negative.  However, 
confirmatory chemical analysis (e.g., gas chroma-
tography/mass spectrometry, HPLC, etc.) in a labo-
ratory could be required for any specimens that 
screen positive. 
In the food industry, the deliberate contamina-
tion of food materials with low-quality, cheap, non-
edible or toxic substances is called adulteration.  
Some adulterants are dangerous to health and can 
even cause death: a recent infamous example is 
melamine that was the source of a Chinese milk 
scandal in 2008.  Fortunately, the first on-site adul-
terant detection devices are now commercially 
available.  Typically dipstick devices, they offer an 
advantage over spot tests because an adulteration 
check can also be performed at the collection site.64  
Intect 7 (Branan Medical Corporation), a dipstick 
covered with seven dry reagent pads, tests for 
creatinine, specific gravity, pH, nitrite, glutaralde-
hyde, bleach, and pyridinium chlorochromate.61b, 65  
Overall, there are more than 50 common adulterants 
that are classified based on their chemical, bacterial, 
or fungal origins. 
 
 
CURRENT CONTEXT OF POC ASSAYS 
POC Glucose Assays   
Glucose measurement is the well-established 
leader in commercial volume for point-of-care test-
ing: glucose test strips for home use are manufac-
tured on an astonishing scale, approaching 
1010/year, with single production lines making de-
vices at a rate of 106/hr using printing and laminat-
ing technology.  The science and technology of 
these devices have recently been described compre-
hensively.31, 66 
The majority of commercial self-test glucose 
measurement systems are now electrochemical, 
based on redox-couple-mediated enzymatic oxida-
tion of glucose with either glucose oxidase or glu-
cose dehydrogenase (GDH), the latter having the 
advantage of faster enzyme kinetics.  Several differ-
ent forms of GDH have been used.  Pyrroloquino-
linequinone-GDH is not specific to glucose, result-
ing in a recent warning about the use of devices 
based on this enzyme for people on certain medica-
tions.67  Advances in recent years have included the 
reduction in time-to-result to as little as 5 s and nec-
essary blood volume to as little as 300 nL, demon-
strating that submicroliter fluidic devices can be 
reproducibly mass-manufactured and applied. 
Glucose detection with these devices relies on 
measurement of a catalytic electrochemical current; 
traditionally-measured electrochemical signals are 
influenced by enzyme reaction kinetics, mediator 
concentration, and sample viscosity (through diffu-
sion coefficients).  Recent commercial develop-
ments have aimed to eliminate these influences, 
such that the precision of measurement is deter-
mined solely by manufacturing dimensional toler-
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ances, an example being the microcoulometer de-
scribed by Heller and Feldman.66b  Calibration of 
strips is by statistical sampling, with the results (en-
coded for example on a barcode) used to set the 
reader gain and offset for strips from a particular 
batch. 
Evaluation of the analytical and clinical per-
formance68 of these devices is a complex question, 
the result depending not only on the performance of 
the device but also on the training of the person us-
ing it, temperature, atmospheric pressure, the way 
the sample is taken, and characteristics of the blood, 
particularly haematocrit69 (red cell content).  The 
current analytical performance requirement is that 
95% of individual glucose results fall within ±15 
mg/dL of a reference measurement at glucose con-
centrations < 75mg/dL, and within ±20% at glucose 
concentrations > 75mg/dL.  Freckmann et al.70 per-
formed a laboratory evaluation of the system accu-
racy of 27 blood glucose monitoring systems using 
two different reference methods; just 16 of the 27 
systems satisfied the performance requirements.  
For the tighter performance requirement deemed 
necessary for tight glycemic control,71 ±5mg/dL for 
glucose concentration < 75mg/dL, the systems var-
ied widely in performance (Figure 3): just 4 of the 
27 systems had 75% or better of their results within 
this range. 
Some variability no doubt reflects limitations of 
the error-compensation algorithms meant to deal 
with sample variability.  Unfortunately, it is not 
possible to identify from the literature what specific 
design variables contribute most.  However, a nota-
ble design assumption is that, during the filling of 
the device and in any pause period before the meas-
urement is initiated, glucose in the sample volume 
is completely converted to gluconolactone as a con-
sequence of a high concentration of enzyme and 
mediator dispersed into the sample, so that the 
amount of reduced mediator corresponds to the 
amount of glucose initially present.  By inserting a 
carbon fiber microelectrode into the sample space in 
two particular commercial devices, Burt and Un-
win72 measured directly the variations of mediator 
concentration at different positions within the strip 
during a glucose determination.  They demonstrated 
unambiguously that the assumption that the enzyme 
reaction proceeds to completion throughout the en-
tire sample is incorrect. 
 
Lateral Flow Assays  
The lateral-flow assay (LFA) or lateral-flow 
immunochromatographic assay, introduced in 1988 
by Unipath, is the commonest commercially avail-
able POC diagnostic format.73  Today, POC LFA 
devices for pregnancy (using hCG levels) and ovu-
lation confirmation, screening for infectious dis-
eases and drugs of abuse, and for measurement of 
protein markers in blood to aid rapid clinical diag-
nostics of life-threatening events such as heart at-
tack, stroke, and deep-vein thrombosis are manufac-
tured in very large numbers: > 107/year for preg-
nancy alone. 
The LFA device incorporates porous mem-
branes, antibodies, and a visible signal-generating 
system; it depends upon fluid migration or flow 
technology as outlined in Figure 4.6b, 73  Generation 
of a response signal begins when a particulate label 
(commonly colloidal gold or dyed polystyrene or 
latex spheres), detectable optically at concentration 
as low as order 10-9 M, is dispersed by flow of sam-
ple into a volume containing analyte that specifi-
cally binds to the label through an adsorbed anti-
body or nucleic acid fragment.  Capture of the ana-
lyte by the label takes place during incubation, after 
which the analyte-decorated label is itself immobi-
 
Figure 3.  Performance of commercial self-test glu-
cose measurement systems, determined under con-
trolled laboratory conditions by Freckmann et al.70 
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lized into a smaller volume.  The concentration of 
captured label in the detection zone thus depends 
upon the flow rate of the fluid past the capture zone 
and the average number of bound analyte mole-
cules/particle, itself dependent on the incubation 
time and kinetics of the capture reaction, which in 
turn depends on the fraction of the particle surface 
covered by active binding reagent.74  With a suitably 
configured system, LODs of 10-12 M are relatively 
easily obtained. 
 
Limitations of “Traditional” POC Ap-
proaches  
POC devices with single-use test cartridges raise 
issues about errors and interferences, but there has 
been relatively little published work on sources of 
error in POC device designs, nor discussion of how 
errors might be affected by system configuration or 
particular unit operations implemented within the 
device.  The myriad processes and their impacts are 
summarized by Figure 5. 
Recently, comparison of POC results with those 
from laboratory clinical analyzers was reported for 
cardiac markers, particularly cardiac troponin I 
(cTnI), a challenging analytical task since it requires 
reliable classification of whole-blood samples near 
a cut-off of 80 ng/dm3 (~ 3 pM)75 of an antigen that 
requires multiple antibody pairs targeted at different 
epitopes.76  Our analysis of the literature indicates 
that critical issues arise in the dispersion of dried 
reagents into the sample, in the mixing of reagents 
and sample, and in the control of incubation time.  
Furthermore, autoantibodies, heterophilic antibod-
ies, and rheumatoid factor are potentially all present 
at variable concentrations in blood samples and can 
cause both positive and negative interference in the 
commonly used “sandwich” immunoassays for 
cTnI.73, 77, 78  Most modern immunoassays therefore 
contain materials that block heterophilic antibod-
ies.77b   In POC test devices, the necessary reagents 
must be contained within the device, usually being 
deposited in dried form within a reagent pad or on 
the base of a channel.  The efficacy with which in-
terferences are handled therefore depends upon the 
efficacy with which the blocking reagents are dis-
tributed through the sample, the concentration uni-
formity of blocking reagent achieved, and control of 
time of incubation with blocking reagent.  Further-
more, POC devices necessarily feature filters to re-
move blood cells, raising the possibility that interac-
tions of blood and filter material, influenced by 
non-analyte blood components that vary between 
samples, can cause variable and unanticipated ad-
sorption of analyte. 
The devices studied feature either variants on 
LFA—on a nitrocellulose strip as in the RAMP (see 
Recent Innovations section) design,79 in a radial 
configuration as in the dendrimer-enhanced radial-
partition immunoassay80 implemented in the Stra-
tus-CS design, or in a microfluidic channel as in the 
Biacore design—or a microfluidic implementation 
of an enzyme-linked immunosorbent assay with 
 
Figure 4. (a) Typical lateral flow immunoassay for-
mat. (b) Sample is applied to the sample pad.  Ana-
lyte present in the sample binds to the antibody-
conjugated label, then binds to the test line to return 
a positive result.  If the analyte is absent, the label 
binds to the control line, generating a negative con-
trol result. (Adapted from Mark et al.7a and Zou et 
al.264) 
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electrochemical detection in the i-STAT design (see 
Blood Chemistry section for a description of this 
technology).  Clinical evaluation of POC devices 
for cardiac markers has focused on reliable risk 
stratification, which has two components: definition 
of a cut-off level for some biomedical marker above 
which the risk of a specified condition is considered 
sufficient for further action, and the precision of 
measurement methods near the cut-off level, which 
determines the probability of both false-positive and 
false-negative results.  These two parameters are not 
independent: definition of a cutoff level requires a 
measurement (with associated probability estimate) 
to be correlated with a clinical outcome.  The 
evaluation of POC devices has therefore involved 
two different aspects: comparison of results with 
reference measurements conducted on laboratory 
analyzers used to define the cutoff, and correlation 
of clinical outcome with measurement results. 
The clinical consequences of variability in ana-
lytical results have been assessed: according to 
Venge et al.,81 laboratory assays identified signifi-
cantly more people with elevated cTnI levels than 
did POC tests (i-STAT and Stratus-CS), and as a 
consequence identified significantly more of the 
people in the study who subsequently died of car-
diovascular disease (80 – 90%) than did the POC 
assays (50 – 60%).  They concluded that “the clini-
cal judgment of the patient with suspected myocar-
dial ischemia should not solely rely on results from 
POC assays.”  This illustrates the difficulties of 
measurement in POC devices where results from 
single-use cartridges depend on batch sampling and 
comparison between different cartridges for calibra-
tion, and where unit operations (particularly mixing, 
incubation timing, sample normalization, and rins-
ing) may not be as well controlled as in a laboratory 
machine.  Over the range 0 – 17 pM cTnI, both 
POC devices had roughly constant standard errors 
of estimate, ~ 2 pM (50 ng/L), relative to the labora-
tory analyzer.81  Both also had very small offset er-
ror, but also a large number of outliers, which 
dominated the regression and contributed to the 
poorer clinical predictive value of the POC results 
relative to the laboratory analyzers. 
In some contrast, Apple et al.82 report participa-
tion by three different hospitals in a patient speci-
men and analytical validation study (n = 186) for 
the i-STAT cTnI assay, yielding a  regression slope 
between the POC device and laboratory analyzer for 
whole blood of 0.9 from 1 pM – 1.5 nM.  The re-
sults on the clinical samples indicated a tendency to 
outliers, with the i-STAT indicating low values rela-
tive to the laboratory analyzer.  However, the stan-
dard error of estimate relative to the laboratory ana-
lyzer over the range 2 – 5 pM, assessed using 
spiked, pooled whole-blood samples, was very 
small, ~ 0.5 pM.  There was no bias between whole 
blood and plasma measurements, both made on the 
i-STAT. 
Bock et al.75 compared cTnI measured by the i-
STAT device with that measured by a clinical labo-
ratory analyzer for 557 specimens that initially 
tested positive by i-STAT.  The study covered a 
very wide concentration range, up to 2 nM.  The 
scatter in correlation was marked at high concentra-
tions; the correlation slope, also dominated by high-
concentration values, deviated significantly from 
unity (~0.6).  Over the narrower concentration range 
0 – 2 pM, near the clinical cutoff, Venge et al.81 
show a correlation coefficient of 0.74.  Bock et al.75 
reported that the i-STAT cTnI test gave generally 
reliable patient classifications.  However, they also 
noted that some 6% of values in the range signifi-
 
Figure 5.  In POC micro-analytical systems, unit 
operations (left-hand side) and overall system 
specifications (right-hand side) interact such that 
decisions on one element affect all others. 
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cant for clinical decision-making, 2 – 4 pM, re-
corded as negatives by i-STAT, were recorded as 
positives by the laboratory analyzer.  Again, this 
work highlights the importance of outliers in the 
results. 
Apple et al. concluded that the i-STAT was a 
satisfactory risk stratification tool (29 positives).83  
Similarly, Lee-Lewandrowski et al. concluded that 
the RAMP device was a satisfactory risk stratifica-
tion tool.84  Examination of the results, as well as 
those of Wu et al.,85 shows the importance of out-
liers.  As noted above, there are many aspects of the 
design of the current POC devices that can give rise 
to such outliers, including the effects of reagent dis-
persion, mixing, timing control and, in lateral flow 
devices, fortuitous cancellation of errors. 
 
ENABLING TECHNOLOGIES 
Printing and Laminating  
In LFA devices, capture agents are printed as 
lines at specific locations on the device membrane, 
followed by a drying process.73  In the traditional 
contact-printing mode, a dispenser tip is dragged 
across the surface of a membrane like a pen while a 
pump delivers a defined volume of liquid.  This 
method can deform the membrane, causing line 
width variation.  Non-contact printing using tools 
such as inkjet printers or micro-solenoid-valve-
controlled print heads has become more common:86  
it provides accurate control of dispensing volume, 
accurate positioning, and flexibility in printing pat-
terns.  However, clogging of the dispenser tip can 
be a problem, since the dispensing solution can con-
tain complex protein stabilizers and/or particles 
such as micron-sized beads.  Proper process optimi-
zation and on-line vision-based inspection are usu-
ally required for the manufacturing process. 
LFA devices and many microfluidic POC de-
vices are fabricated using standard film lamination 
techniques.  In the LFA device, the absorbent pads 
and porous membranes are traditionally laminated 
to a plastic sheet for structural strength using pres-
sure sensitive adhesive (PSA); the stack is then cut 
into test strips that are placed in plastic housings. 
In recent years, lamination of polymer layers 
has been used for the fabrication of a new genera-
tion of microfluidics-based POC devices because of 
its versatility and low cost.87  In one approach, mi-
crofluidic channels are formed in a PSA or thermo-
bond (“hot melt”) adhesive sheet using cutting in-
struments such as a CO2 laser, metal-blade die cut-
ter, or computer-driven vinyl cutter.  The PSA is 
then laminated between two plastic sheets, with the 
PSA material forming the sidewalls of the fluidic 
channel and the PSA thickness defining the channel 
thickness.88  Fluidic channels 50 !m tall with varia-
tion of less than 5% can be achieved.66b  This is im-
portant because accurate volume control is needed 
for most quantitative assays.  PSA also allows 
bonding of different materials, such as polycarbon-
ate or nylon filters and cellulose membranes to a 
plastic sheet.89  Three-dimensional microfluidic 
structures can also be formed using this approach by 
laminating multiple layers of plastic sheets with via 
holes and PSA together.  For example, recent re-
ports demonstrate a fully integrated immunoassay 
card with dry reagent storage, conjugate pad, and 
microfluidic channels, enabling quantitative assay 
with the POC cartridge.90  The cartridge carries dry 
reagents that are reconstituted upon use, eliminating 
the need for refrigerated storage conditions. 
It is common for capture DNA to be robotically 
spotted—in effect a form of printing—onto the 
solid substrate in predetermined spatial locations.  
The spots, with volumes as low as 1 nL, typically 
dry very quickly; spotting variability upon drying is 
not fully understood and it is very likely a situation 
of kinetic control, which can be a significant source 
of the signal variation.91 
A unique new approach uses paper laminated 
with PSA to form 3D fluidic networks for POC de-
vices, claimed to be suited by virtue of their low 
cost to applications in the developing world.92  Nar-
row hydrophilic conduit pads are defined in cellu-
lose paper by hydrophobic borders formed with 
various techniques including photolithography, 
etching, and wax printing.  Various assay reagents 
are printed in the micro-channels on layers of paper; 
the paper layers are then laminated together using 
PSA with via holes filled with cellulose powder to 
wick liquid between paper layers.  Sample is intro-
duced at one end of the paper pad and wicks into 
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the hydrophilic fluidic channels.  Multiple function-
alities including sample preparation and multiplex-
ing have been achieved with this platform. 
Typical PSA-based lamination approaches have 
significant limitations: channel widths are often 
larger than 400 !m and the side walls are not par-
ticularly smooth (on a micron scale) due to the lim-
ited resolution of most cutting tools.  Adhesive ma-
terial compatibility and thermal compatibility can 
also be problematic.  Direct thermal lamination 
(bonding) of plastic films and monoliths to one an-
other can address these limitations.93  Thin plastic 
films of poly(methylmethacrylate) (PMMA), poly-
styrene, and cyclo olefin polymer or copolymer 
(such as Zeonor or Topas) can be laminated to in-
jection-molded or hot-embossed micro-structures 
using heated roller laminators;92 solvent vapor 
bonding is feasible as well.94  These approaches 
produce sealed microfluidic channels with well-
defined walls and tight dimensional control. 
 
Microfluidic Technologies and Approaches: 
“Unit operations” for POC devices  
Microfluidics has been a significant component 
of recent research activity in POC diagnostics.  
Enabling technologies around microfluidics have 
been reviewed recently,95 including centrifugal mi-
crofluidics,96 integration of functionality into poly-
mer-based microfluidic devices produced by high-
volume micro-molding techniques,97 unconven-
tional low-cost fabrication and patterning tech-
niques for point of care diagnostics,87 rapid device 
prototyping,98 flexible99 and thermoplastic100 sub-
strates, and laser-printer toner and paper-based fab-
rication techniques.101  Microfluidic whole-blood 
immunoassay methods,3b including methods of cell 
and particle separation102 and methods directed at 
cardiac marker measurement103 have been reviewed 
as has urine analysis104 and the emerging field of 
salivary diagnostics,105 with discussion of prospec-
tive POC applications. 
 
Pumping and Valving.  Micropumps and mi-
crovalves enable precise control of sample, buffer, 
and reagent flow and delivery.  They are necessary 
for many next-generation POC devices that inte-
grate features such as sample preparation, complex 
assays that include incubation, mixing, or separation 
steps, and more quantitative outputs.52b, 106  Fluidic 
pumps and valves can either be integrated into the 
disposable POC device or into the detection instru-
ment, provided steps are taken to avoid their con-
tamination by diagnostic samples.  Both approaches 
increase cost and can add challenges to device 
manufacturing and introduce new modes of poten-
tial malfunction,107 so the added performance must 
be at least commensurate with these drawbacks. 
To date, most common POC devices, most no-
tably LFA test strips, rely on capillary-force-driven, 
passive fluidic flow.  LFA strips move samples and 
analytes using the wetting properties of capillaries 
in porous substrate materials or integrated wicking 
pads86 or, more recently, arrays of microfabricated 
pillars or posts.108  Their advantages include sim-
plicity in design, compact form, low cost, dispos-
ability, absence of moving parts, and no need for 
external power.  Their limitations are variations in 
flow rate due to sample viscosity variations, site 
temperature, changes in the surface properties of the 
device over time, and poor batch-to-batch repro-
ducibility of substrate materials such as nitrocellu-
lose.  To control flow rate precisely, Cesaro-Tadic 
et al. used Peltier elements to modulate the evapora-
tion rate at the end of a capillary network.109  In mi-
crofluidic devices, rates of capillary-pressure-driven 
flow can also be manipulated by controlling channel 
geometry, using integrated micro-structures, and via 
surface chemistry, as reviewed in detail by Eijkel et 
al.110  Recent work by Gervais et al. demonstrated a 
one-step immunoassay with a fully integrated mi-
crofluidic device consisting of a sample collector, 
delay valves, flow resistors, and capillary pump.111  
Wang et al. also demonstrated a quantitative multi-
plexed protein barcode-readout assay including on-
chip plasma purification from whole blood samples, 
all with capillary force generated via absorbent pa-
per.3a 
External pumps, such as diaphragm pumps, 
peristaltic pumps, and syringe pumps, are common 
in research-based POC devices.89b  They offer the 
advantage of precise flow rate control, but integra-
tion of a pump into the detection instrument can 
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limit home care or field use.112  Miniaturized peri-
staltic pumps (http://www.takasago-
elec.com/products_pump/peristaltic/) provide a 
much smaller version of this laboratory workhorse, 
with its advantage of tubing being the only wetted 
material, but without the capability to replace the 
tubing as in larger pumps.  Microfabricated recipro-
cal and rotary displacement pumps113 can be inte-
grated directly into fluidic cartridges, and offer ad-
vantages of compact size and large flow rate and 
pressure ranges; however, their complexity, cost, 
and power needs can be an issue for POC applica-
tions. 
Low-cost pumping mechanisms that can be built 
into POC devices without electrical power or mov-
ing parts are discussed in a pair of excellent re-
views.52b, 112  They include human-powered on-chip 
finger pumps, chemically-induced pressure/vacuum 
pumps, and spring-based pumps.114  Commercial 
diagnostic products based on such mechanisms in-
clude POC cards by Micronics.115 
Poly(dimethylsiloxane) (PDMS)-based fluidic 
networks connected to arrays of external pneumatic 
valves, extensively developed by Quake and col-
leagues, can provide both valving and peristaltic 
pumping to control on-chip liquid flow precisely.116  
While the instruments required to control the net-
works and the need for a pneumatic pressure source 
limit the use of such devices for POC 
applications,117 these devices may be suitable for 
benchtop diagnostic applications, such as DNA 
analysis.118  Recently, Lee et al. demonstrated in-
corporation of silicone tubing in an injection-
molded plastic device for use as a micro-pinch 
valve for RT-PCR-based HIV detection.119  Zhou et 
al. (at Rheonix, Ithaca, NY) also reported fabrica-
tion and characterization of micropumps through 
pneumatic actuation of thin polystyrene film.120 
Spinning CD-like fluidic disks transport samples 
and reagents by the interplay of centrifugal, capil-
lary, and Coriolis forces; their application in POC 
and POC-relevant applications has been detailed.4c, 
96, 121  This technology has been used for clinical 
analysis for some 4 decades;96, 122 currently, Abaxis, 
Inc. sells the Piccolo portable clinical chemistry 
system (Figure 6) for on-site patient testing of 
multi-chemistry panels in 100 !L of whole blood, 
serum, or plasma (http://www.piccoloxpress.com/). 
Fluids can be pumped toward the rim of the disk 
at a wide range of flow rates through control of the 
spin speed, channel dimensions and surface energy 
(contact angle), and various geometric details, with 
temporary capillary “stop valves” (created where a 
channel abruptly widens or enters a chamber) 
opened to fluid passage simply by increasing rota-
tional velocity.  Steigert et al. demonstrated a sys-
tem with integrated sample preparation including 
separating plasma from whole blood, mixing, me-
tering of liquid, and integrated signal enhancement.  
Rapid detection of glucose, hemoglobin, and alco-
hol in human whole blood was reported.123  New 
developments in the field include integration of the 
fluidic CD platform with other technologies, such as 
carbon electrodes for dielectrophoresis,124 and re-
ports of new immunoassay-based assays from 
whole blood.125 
Fluid droplet-based (or “digital”) microfluidics 
has many (potential) applications in POC diagnos-
tics.126  Droplets moved by the electrowetting-on-
dielectric (EWOD) method are particularly promis-
ing, offering electrically-controlled liquid move-
ment and adaptability to a range of different bioas-
says.127  Droplet generation, mixing, sorting, and 
splitting are controlled by a network of electrodes 
covered with a dielectric coating.  Sista et al. dem-
onstrated rapid immunoassay and on-chip extraction 
and PCR using whole-blood samples with a hand-
held instrument and disposable chips.47  There are, 
however, some limitations on the use of the device 
 
Figure 6.  Abaxis Piccolo Blood Analyzer and CD 
platform.  (Reprinted with permission from Abaxis, 
Inc.) 
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for whole blood samples due to protein surface ad-
sorption, which was avoided by encasing whole 
blood sample droplets in silicone oil.  Companies 
such as Advanced Liquid Logic are developing 
POC products based on such technologies. 
Electrokinetically-based approaches for fluidic 
movement and separation of charged species have 
been used many years for a range of applications, 
including diagnostic assays,128 with explicit consid-
eration of suitability for POC application of elec-
troosmotic pumping, capillary electrophoresis, elec-
trochromatography, or electrokinetically controlled 
immunoassay.7b, 129  In addition to traditional DC-
powered systems that require high voltages (tens to 
hundreds of volts, easily supplied by small, high-
efficiency power supplies), recent developments in 
AC approaches such as electrothermal flow and AC 
electroosmosis also offer potential for POC applica-
tions.107  Sample salt concentration can affect the 
flow rate and, if high enough, can prevent, elec-
trokinetically based approaches, but Huang et al. 
demonstrated low-power AC-based electroosmotic 
pumps that move fluid in a high-salt DNA solution 
without passing current through the salty fluid.130 
 
Mixing.  Resuspension of dried regents, sample 
dilution, and reaction of multiple reagents in POC 
devices often require rapid and efficient mixing.  
However, mixing in microfluidic platforms is diffi-
cult because Reynolds numbers are low (< 1) so that 
flow is laminar and mixing is dominated by diffu-
sion unless special measures are taken; efficient mi-
cromixing can be achieved through a number of ac-
tive and passive mixing mechanisms.131  In active 
mixing, external driving forces such as acoustic 
waves, magnetic beads coupled to moving perma-
nent magnets, or actuated air bubbles enhance mix-
ing of samples.  In passive mixing, liquids are 
driven through microstructures designed to increase 
contact area between the different streams and to 
speed diffusive, or induce chaotic, mixing.  For ex-
ample, structures such as the staggered 
herringbone132 or modified Tesla structure, which 
divides a flow into two streams that collide from 
opposite directions133 have been demonstrated to 
enhance mixing efficiency.  There are some excel-
lent recent reviews on mixing in microfluidic plat-
forms in the context of POC devices.6a, 52b, 131, 134  
Some recent advances in mixer design relevant to 
POC devices are presented here. 
Lien et al. presented a membrane-based mi-
cromixer relying on air actuation to expand and 
compress a series of chambers, creating gentle mix-
ing in fluidic channels as part of a platform for leu-
kocyte purification, DNA extraction, and genotyp-
ing from whole blood.135  Air-induced actuation of 
multilayer PDMS chambers is also used for mixing 
in urine analysis devices as reported by Lin et al.118  
In acoustic mixing, Ahmed et al. introduced a new 
mechanism using an external piezoelectric trans-
ducer to oscillate bubbles trapped along the side 
walls of microfluidic channels to produce rapid 
mixing.136  Recently, Nath et al. demonstrated a 
mixing component by direct integration of a PZT 
(lead zirconate titanate) disk with a laser-cut PSA-
based mixing chamber to achieve rapid mixing us-
ing trapped air bubbles.137 
POC platforms that utilize electrical connections 
or centrifugal forces for pumping, separation, and 
detection often utilize platform-specific mixing 
strategies.  For example, systems that use elec-
troosmotically-driven flow can enhance mixing by 
introducing restrictions in the microchannel and us-
ing an AC electric field to generate alternating thin 
crescent-shaped layers of the two fluids that signifi-
cantly increase the contact area between the two 
streams.134a  In droplet-based microfluidic plat-
 
Figure 7.  Demonstration of mixing in a flat Y-
geometry paper mixer.  (Reprinted with permission 
from Osborn et al.148) 
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forms, mixing is achieved easily by merging indi-
vidual droplets.47, 127, 138  Unique approaches to 
solving mixing issues in CD platforms using Corio-
lis-force-induced mixing, rapid oscillation of the 
disk, and magnetic beads have been reviewed in de-
tail.4c, 96 
Recent advances in passive mixing focus on de-
sign optimization to enhance mixing efficiency in 
short fluidic channel lengths.139  Tofeberg et al. pre-
sented a new design that combines both splitting 
and recombining liquid streams with microfabri-
cated structures in the channels to enhance 
mixing.140  Tsai et al. demonstrated the use of a 
combination of baffles and a curved channel to en-
hance mixing;141 Long et al. presented a 3D vortex 
micromixer consisting of a single mini-cylinder 
mixing chamber.142  Improvement in mixing effi-
ciency also can be achieved through modification of 
channel surface energy: Swickrath et al. demon-
strated high-efficiency passive mixing by a check-
erboard pattern of hydrophobic and hydrophilic re-
gions in a microfluidic channel.143  Photopatterned 
porous polymer monoliths in channels144 are an-
other approach to enhance mixing and improve 
overall chemical reaction rates.  Micromixers with 
passive intestine-inspired serpentine structures were 
integrated with capillary electrophoresis for patho-
gen DNA detection at the single-cell level.145  Choi 
et al. reported a disposable agglutination device for 
clinical diagnostics using a serpentine 
micromixer.146  The use of micromixers containing 
a combination of nozzles and 3D pillars reportedly 
shortened DNA ligation time from 4 hours to 5 min-
utes.147 
Mixing mechanisms that are simple, requiring 
few or no moving parts, are particularly important 
for in-home POC devices and developing-world ap-
plications.  Mixing was demonstrated on a paper-
based POC platform by simply stacking porous pa-
per strips on top of each other in a flat Y-geometry 
mixer (Figure 7).148  Cotton threads with knots used 
for routing and mixing were demonstrated for po-
tential urine and blood analysis applications.149 
 
Separation.  The genesis of modern microfluidic 
and lab-on-a-chip devices is closely linked to sepa-
rations of bio/chemical species on chip, in particular 
using electrophoresis.  LFA, a dominant POC tech-
nology, is often referred to as lateral-flow immuno-
chromatographic assay, emphasizing its separations 
functionality.  Separation is important for POC de-
vices: it can increase target purity, in the process 
improving LODs and removing interferents—
background and potential false positives—by sepa-
rating them from the analytical target prior to detec-
tion.  Separation is also increasingly critical to POC 
methods as detection of multiple analytes in one 
device gains importance (see the Trends, Unmet 
Needs, and Perspectives section). 
Several reviews have described the present state 
of chip-based separations methods in the context of 
the components, or “unit operations”, of microflu-
idic devices.7a, 6a, 118, 134b, 150  Recent developments 
in electrophoretic separations on microfluidic de-
vices have also been reviewed;151 Hou and Herr re-
viewed lab-on-chip affinity-based electrokinetic 
separations for quantitation of proteins and integra-
tion of preparatory functions needed for subsequent 
analyses of biological samples.7b  The use of micro-
fluidic methods to separate cells has been reviewed 
as well.152  Immuno separations are an inherent 
component of LFA, which has been reviewed re-
cently.5c, 73, 153 
Separation methods applied to POC devices and 
POC-precursor microfluidic devices include capil-
lary electrophoresis (CE), dielectrophoresis (DEP), 
isoelectric focusing, various types of liquid (elec-
tro)chromatography including micellar electroki-
netic chromatography (MEC), optical fields includ-
ing tweezers and various particle-motivating fields, 
magnetic motivation and capture, acoustic waves 
and fields, size-based filtration (using filters, nanos-
tructures and microstructures), and various combi-
nations of flow, diffusion, and sedimentation-based 
phenomena—the last of these particularly in cen-
trifugal devices.  Some of these methods are better 
suited to separating molecules, others to particles 
(including cells), and some work for both. 
Separation is based on one or more parameters 
including charge, polarizability/dielectric properties 
(at AC or optical frequencies), pK/pH of minimum 
charge, mass, size, magnetic properties, and physi-
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cal/chemical/immuno binding interactions.  Im-
muno- or chemical binding is often used to selec-
tively tether the analyte to a particle or label, which 
may then enable its separation.  Common separation 
metrics include resolution, efficiency, purity, and 
throughput. 
Two processes closely related to separations—
because they use many of the same phenomena to 
implement differential affinity—are treated in the 
next section, Sample Preparation.  Here we summa-
rize some relevant recent advances in separations, a 
number of which are essentially efforts to integrate 
established separation methods with various fluidic 
components or unit operations, rather than the de-
velopment of new separation methods per se. 
Jung et al. reported a single-cell-level, multi-
pathogen detection device using a DNA barcode 
assay.  It includes target pathogen magnetic separa-
tion as well as capillary electrophoretic separation 
of DNA barcodes, with a total analysis time of 30 
min.145 
The use of an ion-permeable membrane for 
chip-based electrophoretic preconcentration fol-
lowed by CE separation of cancer marker proteins 
was described by Nge et al.154  A negatively 
charged membrane, photopolymerized near the in-
jection intersection of a chip-based CE separation 
structure, concentrated the target components: can-
cer markers !-fetoprotein and heat-shock protein 90 
were concentrated over 10-fold in 1 min, then sepa-
rated by CE. 
In a system designed to detect biological toxins 
using chip-based immunoassays, polymeric gels 
with large pores were located adjacent to a size-
exclusion membrane in order to electrophoretically 
separate antibody–analyte complex from the excess 
antibody prior to detection.1 
Laurell and colleagues reviewed the transition 
of acoustic standing-wave techniques from the 
macro to the micro scale, describing different parti-
cle separation modes and surveying potential appli-
cations in the medical clinic.155 
 
Reagent Storage.  To make the leap from lab-
on-a-chip to practical POC devices, an often-
overlooked necessity is the means to store reagents 
for extended time periods on or in the device.118  
Reagents, including “fragile” molecules like en-
zymes and antibodies, can be stored in wet or dry 
state.  The latter is often preferred in those cases 
where drying (or lyophilization) does not cause total 
and unrecoverable loss of activity, because reagents 
that are successfully dried typically exhibit im-
proved stability relative to those stored wet.52b, 112, 
156  The importance of such storage in the context of 
global health diagnostics was cited by Yager.89b 
In many regards, on-chip storage of dry reagents 
is well developed: LFA strips are dry and include 
reagents—typically at least one type of antibody 
and often two—and other reagents as well.  Glucose 
sensors include dried glucose oxidase and electron-
transfer catalysts.  There is not, however, a single 
best process for freeze drying, lyophilizing, or oth-
erwise depositing and drying reagents in a form 
from which they are readily reconstituted; the suc-
cessful approach often depends upon details of the 
reagents, the sample, and the assay.  The addition of 
sugars, trehalose being a favorite, is a widely util-
ized method to improve bioreagent stability and re-
tention of activity.52b, 112, 156  Immobilization of rea-
gents on beads can facilitate storage of reagents in 
dry form while removing a solution spotting step 
from the manufacturing process.  For example, pro-
tein G beads dried with 80% sucrose were shown to 
be stable for at least 1 month of storage at 45 °C by 
McKenzie et al.157 
An approach reminiscent of LFA methods for 
on-chip reagents was reported by Stevens et al.89a in 
their microfluidic device implementation of a flow-
through membrane immunoassay with on-card dry 
reagent storage.  It utilized both a porous membrane 
patterned with capture molecules and a fibrous pad 
containing an anhydrous analyte label; unlike LFA 
strips, this device relies upon an external pumping 
and imaging instrument to deliver sample and rehy-
drated reagent at controlled flow rates, thereby pro-
ducing more quantitative results.  With developing-
world applications in mind, the malarial antigen 
Plasmodium falciparum histidine-rich protein II 
was stored and reconstituted; gold–antibody conju-
gates were dried in sugar matrices, retaining 80 – 
96% of their activity after 60 days of storage at ele-
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vated temperatures.  The integrated system gave a 
respectable detection limit in the sub-nanomolar 
range in under nine minutes.  
A plasma fibrinogen assay was implemented on 
a polymer micropillar-based LFA platform by drop-
casting a mixture of bovine thrombin and the sur-
factant Triton X-100 onto the dextran-coated plat-
form and air drying.158  The on-chip thrombin suc-
cessfully stimulated generation of fibrin from fi-
brinogen in plasma, leading to clot formation, but 
chips had to be stored at 4° C to ensure reagent sta-
bility.  Using the same dextran-coated pillar-based 
platform, an assay for CRP was implemented by 
immobilizing !CRP antibody in 1% trehalose solu-
tion in a line across the chip using a multipass nano-
droplet spotting approach to reduce band broaden-
ing.108  This pillar platform was also used for an in-
terferon-" LFA assay via deposition and drying of 
anti-interferon-" capture antibodies and rabbit anti-
mouse antibodies for the target and control lines, 
respectively.159 
Despite an ever-expanding menu of success in 
storing biological reagents onboard POC devices, 
fluid in excess of that contained in a blood, saliva, 
or urine sample is often required for more complex 
assays.  Large fluid volumes require off-chip stor-
age, but small volumes can be stored within the de-
vice with appropriate sealing and release methods.   
Blister pack technology, well developed by the 
pharmaceutical industry, has long been a part of 
POC technology and has recently been reported as a 
component of lab-on-chip systems.160  Caution must 
be exercised when implementing liquid storage us-
ing polymer films, many of which have significant 
permeability to water vapor; PDMS is among the 
very worst in this regard.  Some fluorocarbons and 
cyclic olefin (co)polymers are significantly better, 
and most any polymer can be rendered impermeable 
by vacuum deposition of a thin film of metal such 
as aluminum.  Garcia-Cordero et al. reported long-
duration fluid storage using integrated CD-laser-
openable thin-film cyclo olefin polymer valves.161 
  
Sample preparation.  Sample preparation, a 
necessary analytical step in POC devices prior to 
analyte measurement, encompasses sample concen-
tration, diffusion, filtration, purification, and frac-
tionation of analytes from analytically noisy back-
ground matrices.  Although large numbers of POC 
devices accommodate unprocessed blood samples, 
the range of assays that can be performed are lim-
ited by a lack of well-developed on-chip sample 
preparation methodologies.162  Blood, plasma, se-
rum, urine, saliva, and other exudates are all tar-
geted in the development of rapid microfluidic-
based diagnostics,89b and, according to the details of 
the assay and measurement to be performed, pre-
preparation of the sample may be necessary.  
Phase extraction and sample concentration.  The 
separation or concentration of analytes based on 
their physical and chemical properties can improve 
detection sensitivity in microfluidic formats.104  Re-
views published on sample-concentration tech-
niques104, 163 include developments in liquid-liquid-
phase extraction, solid-phase extraction (SPE), iso-
tachophoresis (ITP), immunoconcentration, dialysis, 
and many more.  Lin et al. reviewed many purifica-
tion and enrichment techniques used in microfluidic 
urine analysis.104  Sikanen et al. developed a drop-
let-membrane-droplet-extraction system to extract 
acidic analytes from urine, followed by capillary 
electrophoresis and laser-induced fluorescence de-
tection on-chip.164  The use of metal ions to separate 
urea from urea-rich protein samples has also been 
explored.165  A five-layer microfluidic system based 
on diffusion, followed by facilitative diffusion using 
metal ions such as Mn2+, Zn2+, and Fe3+ allowed for 
efficient urea removal.  Another droplet-based mi-
crofluidic system for the passive isolation of T lym-
phoma cells used PEG droplets that completely en-
capsulated dextran droplets within a microfluidic 
channel, partitioning the cells into the PEG phase as 
they remained in the aqueous droplet.166 
Capture and purification of RNA via its affinity 
for SiO2, using silica beads immobilized in polymer 
microfluidic devices, was accomplished for viral 
RNA from mammalian cells infected with influ-
enza-A (H1N1)167 and for E. coli RNA with patho-
gen-specific response in under 3 min from the RNA 
of 100 bacteria using real-time NASBA (nucleic 
acid sequence-based amplification) for specificity 
and amplification.50c 
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The application of solid-phase extraction to 
separate and detect psychotropic drugs in plasma 
samples in a microfluidic format was evaluated.168  
Microfluidic HPLC separation of proteins and pep-
tides has also been established using both methacry-
late and styrene-based monoliths.169 
 
Cell selection and sorting. Accurate, fast, and 
affordable analysis of whole blood is important in 
clinical diagnostics; however, most analyses require 
the pre-separation of red blood cells from plasma 
due to the interference caused by the cellular com-
ponents of blood with some measurement tech-
niques, e.g. absorbance and fluorescence.  Centrifu-
gal microfluidics offers on-chip autonomy: red 
blood cells can be separated from plasma using dif-
ferences in cell density and centrifugally driven 
sedimentation.96, 117, 121c, 125  Plasma separation as 
part of a centrifugal whole-blood immunoassay sys-
tem has been reported as well.125 
Diffusion phenomena have been used in combi-
nation with flow in microfluidics to separate 
smaller, faster-diffusing molecules from larger ones 
that diffuse more slowly, for example to extract 
small molecules from whole blood.170  A recent pa-
per revisited the concepts of the so-called H-filter 
and T-sensor technologies and their potential use in 
size-based extraction of molecules from complex 
mixtures.148 
Toner and Irimia summarized the unique re-
quirements and challenges of blood cell separation 
in the context of whole-blood diagnostic devices.52  
An integrated microfluidic blood analysis system 
that allows for the separation of plasma from whole 
blood samples (< 5 !L in volume) using channels 
and gravitational sedimentation of red and white 
cells into filtering trenches (99.9% separation effi-
ciency) on a PDMS chip was recently reported.171  
Separation of plasma from whole blood by a 
“skimming” process was reported in an integrated 
device using barcodes for multiplexed protein 
analysis from !L blood samples.172  Continuous en-
richment of platelets from diluted whole blood us-
ing DEP exploited the fact that platelets are signifi-
cantly smaller than other blood cells.173 
Cell selection also encompasses the use of anti-
bodies to capture target cells in miniaturized de-
vices.  Shah et al. reported the specific binding of 
CD8+ T-lymphocytes on an EWOD platform using 
antibody-conjugated magnetic beads.  Fluid move-
ment controlled by electric signals allowed for close 
contact between cells and magnetic beads in the 
droplet, allowing for high binding efficiencies.174  
Magnetic beads coated with antibody have been 
used in the capture and separation of Salmonella 
and Staphylococcus aureus57 with an effective en-
richment factor of ~ 700 – 1600, depending on the 
starting concentrations and ratios of the two cell 
types.  Though significant, this ratio illustrates the 
challenge of detecting a rare target in the presence 
of a very common one: a 1000-fold advantage in 
many cases is inadequate.  
Cell lysis.  The disruption of cells can be 
achieved on-chip by a variety of different mecha-
nisms including mechanical or chemical lysis.  
Vandeventer et al. recently reported on the effi-
ciency of the OmniLyse, a small battery-operated 
disposable bead blender for lysis of thick-walled 
Bacillus spores and Mycobacterium cells in nucleic-
acid testing.175 
A combined chemical/mechanical method for 
lysis of bacterial cells was reported, where bacterial 
samples are sheared as they pass through a porous 
polymer monolith containing detergent lytic condi-
tions, resulting in a concentrated DNA eluent for 
PCR diagnostics.176  Stachowiak et al. used thermo-
chemical lysis, a combination of lysis buffer and 
high temperatures, for protein in their autonomous 
microfluidic chip for protein profile-based detection 
of Bacillus subtilis cells and spores.177 
Electroporation allows for the disruption of cell 
membranes and is used for lysing cells in microflu-
idic devices.  Bao et al.178 used electroporation to 
release calcein and protein kinase from cells in a 
PDMS microfluidic chip. 
Cell lysis by means of a low-voltage electrical 
device on chip was demonstrated by Lee et al.179 
and another group explored the electrolysis of saline 
solution to generate hydroxide ions (OH–) at the 
cathode of the electrochemical device as alkaline 
lytic agents.180  In another innovative approach, la-
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laser irradiation of magnetic particles (Figure 8) 
was used for rapid lysis in the extraction of DNA 
from E. coli and Hepatitis B virus.181 
Cell lysis has been performed using an opti-
cally-induced electrical field in a microfluidic 
chip.182  Fibroblasts and oral cancer cells were ex-
posed to an external electric field, which induced a 
transmembrane potential causing disruption of the 
cell membrane. 
Nucleic acid purification.  In conventional PCR 
diagnostics, sample preparation steps such as DNA 
extraction are time-consuming procedures requiring 
experienced personnel. Recent developments to 
overcome sample pre-processing include the incor-
poration of sample-purification steps on-chip for 
DNA extraction from whole blood.  An integrated 
microfluidic platform that incorporates rapid leuko-
cyte purification, genomic DNA extraction, and 
gene analysis has been reported.135 Magnetic beads 
coated with CD15/45 allowed for purification and 
concentration of leukocytes; DNA was then ex-
tracted using surface-charge-switchable DNA-
specific magnetic beads in the lysis solution; finally, 
PCR amplification yielded a turnaround time of 20 
minutes.135  The use of silica-coated magnetic beads 
to extract DNA in a microfluidic chip has been re-
ported.  DNA binding affinity is high in the pres-
ence of high salt concentrations; the captured DNA 
is released when the salt concentration is reduced.183  
A chip without complex DNA purification steps 
was introduced by Manage et al.: unprocessed ge-
nomic and viral DNA from a whole blood sample 
was amplified on a three-layer glass chip containing 
a PDMS membrane for pumping, which interfaced 
with a miniaturized PCR instrument.184 
Protein preparation.154  Martino et al. investi-
gated the use of microdroplet technology to analyze 
intracellular proteins:185 cells were introduced onto 
the microchip and electrically lysed, followed by 
incubation with antibody-labeled beads in water-in-
oil droplets.  Protein binding to the beads was then 
monitored fluorescently within the droplets.  
Isoelectric focusing has been incorporated into a 
microfluidic device for the separation of proteins 
suspended in a microvolume droplet between two 
Pd electrodes using pH gradients created by elec-
trolysis of buffers with low voltage.186  The anode 
fraction was found to be depleted of high-pI pro-
teins and the cathode fraction of low-pI fractions, 
indicating this technique’s utility in the purification 
of proteins in small-volume samples. 
 
Surface Chemistry and Device Substrates 
Despite the important technological innovations 
described above, considerable progress is required 
to realize the selective, high-affinity, high-binding-
capacity analyte capture methods necessary to push 
the performance of POC diagnostic devices forward 
and so enable new applications.  Nonspecific 
adsorption of proteins and other compounds is a 
critical problem: typically, it effectively controls the 
background response, directly regulating device 
LOD. 
Recent trends in the development of 
immunoassays and biosensor surfaces favor 
polymer materials over glass, mainly for reasons of 
cost,187 although in some cases—e.g., whole-blood 
assays, where silica surfaces trigger rapid clotting—
for biochemical compatibility as well.  Although 
existing chemical methods to prepare biomolecule 
microarrays on glass can, and have been, modified 
to suit polymer surbstrates, new immobilization 
strategies have been developed to adapt and often to 
 
Figure 8.  Magnetic beads conjugated to target-
specific antibody mixed with sample solution.  Tar-
get pathogens are selectively captured on the mag-
netic beads and laser irradiation (808 nm, 1.5W) 
for 30 s enables DNA extraction from captured 
pathogens (Reprinted with permission from Cho et 
al.181) 
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take advantage of the specific physico-chemical 
properties of the plastic materials.4a, 188 
 
Physical Adsorption.  Random interfacial 
adsorption of biomolecules represents by far the 
most common immobilization technique in the POC 
device industry.  Molecules typically adsorb on 
surfaces through ionic bonds, hydrophobic, polar, or 
electrostatic interactions.189  While this is the 
simplest method for capturing biorecognition 
elements, different antibodies raised against the 
same antigen can show very heterogeneous binding 
affinity, undergoing structural changes and 
exhibiting inadequate orientation of binding 
epitopes upon adsorption. 
The emergence of surface-specific analytical 
systems has enabled the study of the effects of 
several factors such as pH, salt concentration, and 
surface excess of antibodies on the binding capacity 
for its specific antigen.190  It is generally accepted 
that when the activity of physically adsorbed 
biomolecules is low, this is due to structural 
unfolding associated with interfacial adsorption.  
Williams and co-workers reported that the main 
factor affecting the antibody-antigen binding is 
related to the surface packing density.191  Apart 
from random orientation, loss of activity, and low 
binding density, an additional drawback of 
adsorption-based attachment is low bond strength: 
physically adsorbed proteins may be removed by 
some buffers or washing detergents during assays. 
 
Bioaffinity Attachment.  The most common 
bioaffinity immobilization reaction is based on the 
specific binding of biotin to avidin and streptavidin.  
This approach exploits the strongest non-covalent 
bond found in nature (Kd = 1.3 # 10–15 M).192  Bio-
tin-functionalized (“biotinylated”) molecules can be 
captured using the appropriate (strept)avidin conju-
gates even in complex media and under harsh con-
ditions during assays.193  The protein maintains its 
structural integrity and activity even in 8 M urea or 
3 M guanidinium chloride.  One of the very few 
disadvantages of using (strept)avidin is its propen-
sity to bind nonspecifically with compounds other 
than biotin due to its high carbohydrate content and 
high isoelectric point.  The use of the (strept)avidin 
– biotin concept in assays has been reviewed exten-
sively.194 
Other popular affinity immobilization tech-
niques, some of which are highlighted in a pair of 
recent reviews,195 include recombinant proteins with 
genetically engineered histidine-tag systems for 
site-specific attachment, protein A/protein G-
mediated immobilization for specific interactions 
with Fc fragments of IgG, and immobilization of 
glycoproteins through their carbohydrate moiety, 
which is typically not involved in specific activity. 
Efforts have been made to produce artificial 
ligand-receptor pairs that mimic naturally occuring 
affinity systems, such as the (strept)avidin–biotin 
interaction. For example, Hwang et al. and 
Rekharsky et al. showed an approach for protein 
immobilization on gold surfaces based on strong 
non-covalent interactions between a host 
cucurbit[7]uril with a hydrophobic cavity and 
ferrocenemnethylammonium or 
adamantylammonium ions: very good host-guest 
affinity was demonstrated with high binding 
constants (up to 1015 M-1) and good specificity in 
aqueous conditions.196  Other potential strategies 
based on reversible host-guest interactions 
exploiting the use of poly-lysine and cyclodextrin 
derivatives,197 supramolecular interactions between 
an adamantane unit and "-cyclodextrin,198 and other 
hydrophobic interactions199 have been reported. 
 
Covalent Attachment.  Proteins can be coupled 
to surfaces by a range of chemical reactions be-
tween an appropriately functionalized solid support 
and many of the complementary functional groups 
in the amino acid side chains.  The most common 
methods for covalent attachment of proteins to sur-
faces include the use of either amine groups of the 
lysine residues or carboxy groups of aspartic and 
glutamic acids.  Typical examples of compatible 
groups on the surfaces and the functional group they 
react with and the related surface performance is-
sues for both nucleic acid and protein microarrays 
are summarized in several reviews.42, 195  Unfortu-
nately, due to a relatively high abundance of both 
amine and carboxy groups on the surfaces of pro-
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teins, this strategy can lead to problems related to 
increased heterogeneity and restricted flexibility 
owing to multipoint attachment.  
 
Substrate Materials. Many current and emerg-
ing POC platforms are based on substrates made 
from organic polymers rather than silica.200  Ther-
moplastics and new polymeric materials including 
derivatives of polyacrylates, polystyrenes, polyeth-
ylenes, and cyclo olefin (co)polymers (COPs, 
COCs) stand out as excellent candidates for micro-
total analysis system platforms and POC diagnostic 
devices.  Their structures can be selected or modu-
lated to provide excellent optical, thermal, chemi-
cal, and biocompatibility properties.201, 202  Plastics 
are used as structural materials for fluidic chips and 
cartridges made by methods such as molding, em-
bossing/imprinting,201, 203 etching/micromilling, la-
ser ablation,204 or die cutting.  For the commonly 
used materials, the pristine polymer surfaces are 
relatively inert, hydrophobic in nature, and do not 
posses groups suitable for reactions with capture 
biomolecules.  They are functionalized, therefore, 
by chemical methods including photografting, oxy-
gen plasma, or UV/ozone treatment, all resulting in 
formation of a thin, oxidized, hydrophilic layer that 
can adsorb proteins and oligonucleotides.188c, 205 
Such surface films, however, contain many highly 
reactive and unstable oxidized species that are read-
ily quenched by any impurities and gases/vapors 
present in air.  Moreover, such prepared surfaces 
provide a low degree of flexibility of the functional 
groups, and flexibility may be needed for proper 
orientation of captured biomolecules.  A typical so-
lution is to functionalize plastic substrates with or-
ganic compounds that can cross-link, polymerize, 
and form a film from one to a few hundred nanome-
ters in thickness.206  Because most polymeric sub-
strates are characterized by low chemical resistance 
to many non-polar organic solvents and relatively 
low melting temperatures, the choice of chemical 
reactions suitable for functionalization of their sur-
faces is limited. 
In general, substrates modified with a range of 
organosilanes have suitable physico-chemical 
properties for immobilizing proteins and other 
biologically relevant molecules.  The organosilane 
precursor covalently couples to the surface via 
formation of Si-O-Si bonds with the functional 
group extending from the surface.207  A number of 
articles have been published on this subject, most of 
them addressing the effect of different deposition 
conditions such as reaction temperature, incubation 
time, concentration, role of solvent, catalyst, 
adsorbed water, or curing.206c, 208  The most 
common techiques rely on activation of the 
disposable substrate by plasma or UV/ozone 
followed by immersion into an aqueous or organic 
solution of the organosilane.  Such methods may 
suffer from a lack of reproducibility in film quality, 
often due to the fact that organosilanes with 
multiple Si-X (X = Cl, Br, methoxy, ethoxy, 
propoxy) tend to polymerize in the presence of even 
trace quantities of water.  The necessity of 
eliminating water from non-aqueous solvents, along 
with the solvent waste generated, makes this 
technique less attractive when bulk quantities of 
coated substrates are required. 
Coatings produced by chemical vapor 
deposition (CVD) techniques are generally 
performed at elevated temperatures,208b and 
therefore are more suitable for silica-based 
materials than plastics.  Significant advances have 
been made in the development of a one-step process 
of surface functionalization based on plasma-
enhanced chemical vapor deposition (PECVD).  
This technique has a number of advantages over 
multistep, wet chemical methods or conventional 
CVD: it can be used to coat a large number of sub-
strates in a single batch, it avoids direct contact with 
solvents, reducing chemical waste, and, impor-
tantly, it operates at room temperature.  Also, no 
major limitations have been observed in the prepa-
ration of homogeneous coatings on curved or pat-
terned surfaces or inside microfluidic channels.209  
This method makes it possible to provide better-
defined structure as well as the desired chemical 
functionality using one material on the device sur-
face.210 
An issue of particular importance to POC de-
vices, due to the increasing prevalence of microflu-
idic structures, is loss of sample analyte by nonspe-
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cific adsorption on channel walls.188b, 211  The manu-
facturing methods and cost constraints required for 
making microfluidic systems beyond laboratory 
volumes constrain the materials that can be used, 
which in turn constrains the nature of the surfaces 
that can be engineered, both to minimize non-
specific adsorption and to maximize specific bind-
ing activity for target capture.  Plasma polymeriza-
tion is an industrially-scalable method for surface 
layers with a variety of different chemical function-
alities, and its application to biochip preparation has 
recently been reviewed.212  AC plasma polymeriza-
tion has been used to deposit poly(ethylene glycol) 
(PEG)-like coatings from an 18-crown-6 precursor, 
and the non-fouling characteristics of these coatings 
have been demonstrated.213  The applicability of 
low-energy plasma-enhanced chemical vapor depo-
sition to prepare surfaces with high specific binding 
activity and low non-specific adsorption has been 
demonstrated.188c, 206  Significant protein analyte 
adsorption onto untreated PMMA surfaces has been 
demonstrated and a low-energy PECVD method of 
making a PEG-like coating from diethylene glycol 
dimethyl ether precursor proved effective as a 
means of minimizing such analyte loss.188b 
 
Detection  
In annual manufactured volume, electrochemi-
cal (billions of glucose strips, millions of blood 
chemistry cartridges) and optical (tens of millions 
of LFA devices for pregnancy and other tests; mil-
lions of fluorescence-based assays for cardiac and 
other disease markers) technologies are the clear 
leaders.  The glucose technology (see above) is an 
example of label-free, indirect detection: the am-
perometrically detected product is a proportionate 
surrogate for glucose concentration in the blood 
sample.  LFA pregnancy tests are labeled assays: 
antibody-based binding of gold nanoparticles pro-
duces a colored line if sufficient hCG is present in 
the urine sample. 
Detection has been reviewed as one component 
of POC or “towards POC” devices.6a, 11a, 106, 214  
Some reviews with substantial detection sections 
are more specifically focused on immunoassay and 
protein/biomarker-based diagnostics;3b, 103, 118, 215 
nucleic acid testing for infectious disease;8b cancer 
diagnostics;216 lateral flow153 and centrifugal96 plat-
forms; and for global health and limited-resource 
settings, where instrumental complexity should be 
minimized.52b, 112 
 
Electrochemical Detection.  Electrochemical de-
tection methods include amperometric, potentiomet-
ric (including self-amplified ion-sensitive field-
effect transistors, ISFETs), and impedimetric215, 217 
measurements.  The first, used for glucose assays, is 
most common and typically generates current in 
proportion to the concentration of the detected spe-
cies; all three methods are used by the modern ver-
sion of the i-STAT chemistry analyzer, depending 
on the target analyte.52b 
While some analytes are electroactive and can 
be measured directly without labeling,218 electro-
chemical detection often utilizes tagging for analyte 
specificity with either an electroactive species or an 
enzyme that converts an electrochemically silent 
species into electroactive one; this approach also 
provides signal amplification of multiple orders of 
magnitude, with detection limits below 1 pM read-
ily accessible.  For example, Hoegger et al. reported 
an electrochemically measured ELISA determina-
tion of the folic acid content of food products.219  
Staphylococcal enterotoxin B was captured with 
specific antibodies and detected via the enzymatic 
production of an electrochemical signal from a sec-
ond specific antibody labeled with horseradish per-
oxidase.220 
Label-free impedimetric sensing was demon-
strated for detection of salmonella at the 1000 
cfu/mL level using antibody binding to capture the 
bacteria on electrodes.221  Myoglobin, indicative of 
cardiac damage, was detected at 100 ng/mL via 
conductivity changes resulting from its antibody-
based capture,222 and similar specific capture of the 
stroke marker neuron-specific enolase, without ad-
dition of a label, was reported at the 0.5 pg/mL 
level.223  Such impedance changes can be measured 
using microfabricated electrodes or, in a device that 
is more a “bioresistor” than an electrochemical de-
vice, via binding to carbon nanowires.224 
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Assays based on nanoparticles bearing DNA 
barcodes225 have been used to specifically detect 
proteins with electrochemical transduction,226 and a 
disposable electrochemical immunodiagnostic de-
vice based on nanoparticle probes, stripping volt-
ammetry, and LFA technology was reported.227  An 
amperometric immunosensor system was devel-
oped, with onboard reagent storage, for the detec-
tion of the breast cancer markers carcinoembryonic 
antigen and cancer antigen 15-3; it was demon-
strated for the analysis of patient serum samples.228  
A thrombin-generation amperometric assay in 
plasma and whole blood has been reported.229  The 
use of electrochemical detection means for LFAs in 
general has been explored.230 
 
Optical detection.  Optical detection methods 
used for POC applications include fluorescence111 
with such variants as Förster resonance energy 
transfer (FRET231) and up-converting phosphor 
technology;232 (chemi)luminescence;57, 233 absor-
bance (colorimetry); surface-plasmon resonance 
(SPR); and various categories of light scattering: 
Rayleigh (particles much smaller than wavelength), 
Mie (particles comparable to wavelength; shape-
dependent), geometric (particles larger than wave-
length), resonant (wavelength overlaps an electronic 
transition of the particle), and Raman (vibrational 
quanta added to or subtracted from the excitation 
wavelength).  Absorbance is by far the commonest 
due to its use in LFAs based on gold or polymer 
(nano)particles, while fluorescence is used for the 
broadest range of different types of POC assays111 
for reasons of sensitivity and, more recently, the 
ready availability of a range of different colors of 
efficient fluorophores, including quantum dots,231a, 
234 quantum-dot barcodes,235 and fluorescent 
nanoparticles,236 providing improved limits of de-
tection—in some cases reaching single-particle 
LODs—and enabling multi-target multiplexing.  A 
recent review by Myers and Lee surveys those re-
cent innovative optical detection techniques that 
meet such POC-relevant criteria as reasonable cost, 
ruggedness, and ease of integration with fluidic 
technologies.237 
A recent variant of fluorescence, so-called su-
percritical angle fluorescence (SAF) detects only 
fluorescence emitted in close proximity to a fluoro-
phore-supporting optically transparent chip sur-
face.238  This method provides substantial enhance-
ment of fluorescence collection efficiency while 
rejecting background from unbound fluors or impu-
rities, as it confines the fluorescence detection vol-
ume to material within about one wavelength of the 
chip surface.  An imaging SAF scanner to detect 
multiple assays on one chip was developed and 
demonstrated using 200-nm-diameter fluorescent 
beads. 
Major recent advances in the variety, quantum 
efficiency, output power, and affordability of light-
emitting diodes and diode-pumped solid-state lasers 
(e.g., as in laser pointers and DVD players) is bring-
ing a wide range of excitation wavelengths to com-
pact POC readers without requiring major compro-
mises to LODs that would be imposed by low-
intensity light sources.  Electroluminescence excita-
tion has also been explored, in one example for de-
tection of botulinum neurotoxin A.239  In another 
example of utilization of recent technological de-
velopment, colorimetric and fluorescent readers 
utilizing smartphone integrated cameras have been 
reported.240 
Most optical methods are based on labeling the 
analyte by attaching a chromophore, fluorophore, or 
particle241 (dye-containing, semiconductor/quantum 
dot, noble metal,231b or scattering) to an antibody or 
nucleic acid strand that confers specific recognition.  
The use of gold nanoparticles in molecular diagnos-
tics was reviewed by Radwan and Azzazy.231b   SPR 
is an exception, requiring only specific adsorption 
of the analyte onto an optically appropriate, target-
selective surface; examples are reported below in 
the Label-Free section. 
Nanoparticles including quantum dots are find-
ing increasing application.  For example, determina-
tion of cancer biomarkers in serum and saliva using 
quantum dot bioconjugate labels was recently re-
ported.234  Quantum dots were employed on-chip 
for CD4+ T-cell counting in a POC application.160  
Aptamers were tethered to gold nanoparticles as 
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part of an LFA-like dry-reagent assay strip to detect 
thrombin.242 
Thermal-lens microscopy (TLM), an alternative 
to fluorescence detection, also benefits from dye 
labeling.  TLM detection was integrated into a 
miniaturized ELISA device including all optical, 
electronic, and fluidic components necessary to 
provide an LOD of 2 ng/mL for total IgE measure-
ment.243 
 
Magnetic detection. Magnetic particles are a 
promising technology for POC diagnostics, because 
they can be used to preconcentrate and localize ana-
lytes, and, although the beads may have different 
optimal sizes or compositions according to their 
function, they can also be used as a labeling tech-
nology for detection without the requirements for 
optical transparency of fluors.  Spurred by advances 
in memory devices, magnetic particle detection 
technology has evolved rapidly,244 the most promis-
ing and sensitive methods now using the giant mag-
netoresistance (GMR) effect with detectors based 
on so-called spin valve (SV) or magnetic tunnel 
junction (MTJ) methods.245  The particles must be 
in close proximity to the detector for good sensitiv-
ity, placing some constraints on fluidic device de-
sign.  Wang and Li review GMR SV sensors for 
magnetic nanotags for biosensing, showing from 
their own results that as few as 14 monodisperse 16-
nm superparamagnetic ferrite nanoparticles can be 
detected by submicron SV sensors at room tempera-
ture.244  Tang et al. reported on the feasibility of si-
loxane-coated CoFe2O4 nanoparticles as the basis 
for a GMR-SV biosensor, with the goal of single-
molecule detection.246 
Philips Research (Eindhoven, NL) reported the 
development of a compact biosensor platform to 
detect biomolecules with superparamagnetic parti-
cle labels using GMR sensors with integrated field-
generating wires.247  The silicon detection chip is 
packaged in a disposable cartridge that integrates 
electrical connections for readout and fluidic sub-
system.  Philips recently reported sensitive detec-
tion of amplified DNA on this system using a 
miniaturized detection platform suitable for POC 
application: using various tag-antibody combina-
tions specific for individual genes, they demon-
strated multi-analyte detection of several antibiotic 
resistance-associated genes of the pathogen salmo-
nella.248 
 
Label-Free Methods.  Methods appropriate for 
label-free POC detection include SPR, devices 
based on mechanical transduction, and direct elec-
trochemical and optical transduction for analytes 
possessing suitable characteristics.  Wang et al.249 
developed a magnetic nanoparticle-enhanced bio-
sensor in conjunction with SPR: a sensor surface 
was modified with antibodies to capture the target 
analyte, $ hCG.  Another microfluidic device based 
on SPR was developed by Nilsson et al.250 for the 
detection of influenza, where recombinant hemag-
glutinin proteins were immobilized on the chip sur-
face and a change in the SPR response was detected 
upon binding of the target.  An immunoassay incor-
porating an electro-microchip, gold nanoparticle 
detection, and silver enhancement for signal ampli-
fication was documented by Su et al.251  High detec-
tion sensitivities were shown with both IgG and 
protein A immobilized on the chip surface. 
Mechanical transducers for POC applications 
oscillate or resonate, including micro- and nano-
cantilevers (reviewed by Waggoner and Craighead 
for environmental and biological applications252), as 
well as various acoustic wave devices such as the 
quartz-crystal microbalance (QCM) and a range of 
devices in the surface acoustic wave family (re-
viewed by Rocha-Gaso et al. for biosensor applica-
tions253).  Operating characteristics such as fre-
quency and signal attenuation for piezoelectric de-
vices, or resistance and amplitude for piezoresistive 
(silicon) devices, are affected by the mass and me-
chanical properties of molecules and materials 
linked to their oscillating surfaces: like SPR, they 
require only an immobilized selective recognition 
layer.  Nonetheless, ‘mass tags’—dense particles 
(typically Au) that bind selectively to the target—
can significantly enhance sensitivity. 
So-called “bond rupture sensors,” reviewed by 
Hirst et al., use acoustic energy to rupture bonds 
between immobilized capture antibodies and target 
microbes.  Because the energy and frequency of 
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added energy can be adjusted, non-specifically and 
specifically-captured particles can be desorbed dif-
ferentially according to the bond strengths and 
masses, providing a unique discrimination mecha-
nism.254 
The use of aptamers as biorecognition moieties 
tethered to QCM biosensors,255 as well as in canti-
lever-based biosensors, has been described.256  Sili-
con microcantilevers are challenged when operating 
in liquids due to damping of their motion, but Ric-
ciardi et al. report better performance for mi-
croplates than microbeams, with a Q factor of 140 
determined for a device that senses the tumor 
marker angiopoietin-1.257 
 
Enabling multiplexed assays.  Detection of mul-
tiple analytes with a single POC test is well estab-
lished in select cases: e.g., for blood chemistry (the 
i-STAT device) and for cardiac damage markers 
(Biosite’s Triage system).  Multiplexed detection is 
a positive differentiating feature in many cases, and 
is a necessity in others: many assays are unreliable 
without a positive control, and some require a nega-
tive control as well. 
Multiplexing can be achieved spatially: detec-
tion of different analytes occurs in different loca-
tions on a substrate, e.g. by patterning spots of dif-
ferent selective-capture antibodies or nucleic acid 
oligomers; by separation prior to detection, e.g. by 
capillary electrophoresis followed by fluorescence 
detection; or by differentiable labels, e.g. different 
emission-wavelength fluors or particles, spectrally 
distinct Raman tags, or distinguishable nano-
barcodes.  One well-developed tool (from Luminex, 
Inc.) is based upon a series of defined ratios of two 
different dyes dissolved in polymer beads: the anti-
body or capture oligomer for a given target is im-
mobilized on beads with a particular dye ratio, and 
readout in a cytometry-like fashion includes identi-
fying the bead type according to the ratio of the two 
dyes (excited by a common wavelength), and quan-
tifying the bound target using a different excitation 
wavelength for a fluorescent label.  This method 
was used in a feasibility demonstration of a POC 
multiplexed saliva-based biochip test for acute 
myocardial infarction.258  Other multiplexed POC 
examples are presented in the Trends, Unmet Needs, 
and Perspectives section.  
 
 
RECENT INNOVATION 
Lateral Flow Assay Technologies 
The limitations of LFAs were discussed above, 
and efforts to address the critical issues of error and 
accuracy should target control of the sample volume 
into which the label is dispersed, uniformity of dis-
persion, and flow rate, which is the main determi-
nant of contact and incubation times.  In fact, a for-
tuitous cancellation of errors can occur because the 
flow rate determines the total volume of label-
containing sample that passes over the measurement 
zone within the fixed measurement time whilst it 
also determines the contact time of sample with la-
bel before the capture step (a higher flow rate 
means a shorter incubation time and hence smaller 
capture efficiency).  Thus, a simple strip design can 
give satisfactory semi-quantitative results, a feature 
exploited by the recently developed ‘digital’ preg-
nancy test system wherein measurement of optical 
density on the capture zone259 is used to estimate 
the hCG concentration260 in the sample, providing 
both an indication of pregnancy and an estimate of 
the time since implantation67  
(http://www.clearblue.com/uk/new-clearblue-
digital-pregnancy-test-with-conception-
indicator.php). 
Different commercial designs for quantitative 
LFA utilize different implementation strategies to 
improve measurements.  In the case of cardiac 
marker detection using the Rapid Analyte Meas-
urement Platform (RAMP™, from Response Bio-
medical Corp., BC, Canada; 
www.responsebio.com), the sample is mixed and 
incubated with label and buffer in a separate tube 
before application to the strip, significantly improv-
ing this aspect of the test.  A ratiometric measure-
ment of the intensity of the test line relative to a 
control line is also made, small variations in the 
flow rate being expected to affect the two lines 
similarly. 
Materials are another area of recent develop-
ment.  Standard LFA materials—nitrocellulose, 
polyester, rayon—suffer from varying degrees of 
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non-specific binding, brittleness, and sensitivity to 
humidity.261  One study of more reliable alternatives 
implemented a coagulation assay on glass and mi-
crostructured COP lateral flow platforms.262  As mi-
croclots formed around the pillars, fluorescently-
labeled fibrinogen was incorporated into the clot.  
The sensitive detection of fluorescence on this de-
vice was correlated to the heparin concentration in 
blood samples. 
A recent advance in traditional LFA devices, 
driven by the demands of increasingly quantitative 
POC applications, is integration of new materials 
with 3D pore structures having well-controlled 
pore-size distributions that enable more consistent 
protein binding and control of fluid flow rates.  For 
example, Whatman’s Fusion 5™ can act as sample 
pad, conjugate release pad, and membrane for test 
and control lines, consolidating the various materi-
als previously used in LFA devices into a single 
material, generally simplifying assay and manufac-
turing process development.86  Capture lines are 
formed by printing 2-!m latex beads conjugated 
with capture agents.  The beads are confined in the 
porous material, and form capture lines with the 
sample and labeled conjugate mixture. 
Challenges with nonspecific adsorption and 
batch-to-batch reproducibility of nitrocellulose and 
other traditional LFA device substrates have driven 
the development of injection-molded plastic chips 
with well-defined microfabricated pillars as an al-
ternative to porous membranes.108  This is the basis 
of the 4CastChip developed by Åmic AB (Uppsala, 
Sweden); the technology was subsequently pur-
chased by Johnson & Johnson/Ortho Clinical Diag-
nostics.  The molded cylindrical pillars, typically a 
few tens of microns in diameter and with similar 
spacing, are made hydrophilic by dextran coating to 
drive capillary flow of sample and conjugate.  The 
pillars also allow covalent linkage of capture pro-
teins for fluorescence-based assay. 
Traditional LFA labels—colored or fluorescent 
particles including colloidal gold and latex or poly-
styrene beads73, 261–have  on occasion been replaced 
with carbon or selenium.7a  More recent advances 
include the use of quantum dots, paramagnetic par-
ticles, upconverting phosphors, and electrochemi-
luminescent labels.6b, 153  Carbon nano-strings, elon-
gated nanoparticles containing smaller spherical 
particles, were used for the ultrasensitive detection 
of DNA in a lateral-flow hybridization assay.263 
A sensitive LFA for the detection of trichloro-
pyridinol, a metabolite marker for exposure to pes-
ticides, was developed using quantum dots, advan-
tageous in this assay for their higher brightness, re-
sistance to photobleaching, and simultaneous exci-
tation of multiple fluorescence colors.264  Quantum 
dots have also been employed in the quantitative 
detection of ceruloplasmin, a biomarker for cardio-
vascular disease and lung cancer.265  Ceruloplasmin 
was combined with quantum-dot-labeled antinitro-
tyrosine and captured by anticeruloplasmin antibod-
ies in the test zone of the LFA to produce a fluores-
cence signal.  A LFA for protein biomarker detec-
tion using a portable fluorescence system with 
quantum dot labels was reported.265 
Song and Knotts reported an LFA using time-
resolved (fluorescence) measurement of bright, 
long-lifetime europium-containing phosphorescent 
nanoparticles conjugated to a monoclonal antibody 
for CRP (an inflammatory marker) in serum over a 
0.2 – 200 ng/mL working range.266  Their portable 
reader prototype detects 2.5 ng of immobilized 
phosphorescent particles with a 1000-fold dynamic 
range. 
Upconverting phosphor technology (UPT) has 
been used to label targets in LFAs.232, 267  UPT uses 
rare-earth-doped ceramic (nano)particles, often 
coated with silica for improved bio/chemical com-
patibility and ease of functionalization, that absorb 
near-infrared light and emit a visible signal.  This 
approach minimizes background signal relative to 
conventional fluorescence labeling.  Two studies 
adapted UPT for increased sensitivity in the detec-
tion of infectious diseases in saliva232, 267 and a third 
integrated UPT with microfabricated COP pillar-
based fluidic devices, instead of the typical nitrocel-
lulose support matrix, to detect the cytokine inter-
feron-" with a 3 pM LOD.159 
Detection in LFAs is no longer limited to optical 
measurements.  One study detected prostate-specific 
antigen (PSA) using an electrochemical transducer: 
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immunochemical events on the assay strip were de-
tected as shifts in capacitance.269 
Development of an LFA/ELISA system based 
on superparamagnetic nanobeads as labels, linked to 
a monoclonal antibody, for rapid detection of cTnI 
was recently reported by Xu et al.270  Magnetic de-
tection measured cTnI binding to the test zone; the 
LOD was 10 pg/mL. 
Commercially available lateral flow assays us-
ing fluorescent labels and FRET for increased sensi-
tivity include the RAMP™ (see above) and the Tri-
age Cardiac Panel from Biosite, Inc. (San Diego, 
CA).  Both enable sensitive detection of cardiac 
proteins such as myoglobin and cTnI in whole 
blood or plasma.6b, 18 
Digital readout LFA systems now integrate the 
means to calculate and display analyte concentra-
tions, offering quantitative data not available from 
standard visual color-change readouts.  Examples 
include Metrika’s (Sunnyvale, CA) Digital Re-
sponse (DRx) for measuring hemoglobin levels6b 
and the Clearblue Easy digital pregnancy test sys-
tem described above. 
 
Proteins  
Antibodies.  Most POC diagnostics are based on 
affinity techniques, with the target analyte captured 
by antibodies.271  An extensive array of antibody-
based POC devices currently exists, as outlined un-
der Diagnostic Targets.  Recent developments in 
the area of antibody-based POC diagnostics include 
research into a broad panel of disease markers, 
novel detection methodologies, and new microflu-
idic formats.  
Commercial antibody-based POC devices have 
most commonly used traditional LFA technology.  
In addition to ultra-high-volume pregnancy and glu-
cose tests, LFA tests have been developed for 
markers of celiac disease: CeliacSure™ from Glu-
tenPro (Mississauga, ON, Canada); BioCard Celiac 
Disease™ from Ani Biotech (Vantaa, Finland).  
Raivio et al.272 reported that whole-blood POC de-
vices compare favorably with conventional sero-
logical central lab-based tests in their comparison 
study of the BioCard Celiac Disease™ microfluidic 
device.  For the diagnosis of hepatitis C, Lee et 
al.273 evaluated the use of the OraQuick® Rapid 
HCV Antibody Test from OraSure Technologies, 
Inc. (Bethlehem, PA).  This technology is an indi-
rect immunoassay method in a LFA device format 
and can be used with venous/capillary blood, serum, 
plasma and oral fluid samples.273 
HIV diagnostics continue to be an active area in 
antibody-based testing.  The Dual Path Platform 
(DPP®) chromatographic immunoassay, developed 
for HIV and syphilis (Chembio Diagnostic Systems, 
Medford, NY; www.chembio.com), combines a 
specific antibody-binding protein conjugated to col-
loidal gold dye particles and HIV 1/2 antigens 
bound to the membrane solid phase.  The INSTITM 
HIV1/HIV2 rapid antibody test (bioLytical, Rich-
mond, BC, Canada; www.biolytical.com) detects 
HIV antibodies in blood, plasma, or serum by sam-
ple application to the on-chip membrane, which 
contains HIV-specific proteins; HIV antibodies 
cause a color change of the membrane spot. 
Commercial devices using latex agglutination 
technologies include the Prolex-Blue from Pro-Lab 
Diagnostics (Richmond Hill, ON, Canada), which 
allows for serogrouping of $-hemolytic strepto-
cocci.  Well-known commercially available im-
munofiltration devices include the NycoCard and 
Afinion systems from Axis-Shield (Oslo, Norway) 
for blood and urine testing of CRP, D-dimer, 
HbA1c, U-albumin, and creatinine.6b  These devices 
work on the principle of filtration through porous 
membranes containing immobilized antibodies that 
detect the target analyte. 
Companies working on the development of POC 
devices incorporating immunoassay technology in-
clude Vivacta (Kent, UK; www.vivacta.com), who 
have brought POC devices to the market for the de-
tection of thyroid-stimulating hormone (TSH) and 
cardiac markers including troponin and brain natri-
uretic peptide (BNP); Chirus (Watford, UK; 
www.chirus.com), who have developed the 
DXpress™ reader for measuring cardiac and preg-
nancy biomarkers as well as drugs of abuse; and 
Philips (Best, The Netherlands), who supply the 
Magnotech device for cardiac and sepsis markers 
(http://www.business-sites.philips.com/magnotech).  
POC optical immunoassays are also available from 
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ThermoBioStar™ (Louisville, CO; 
www.thermofisher.com) for the detection of Neisse-
ria gonorrhea and group B Streptococcus.  Immu-
noassay cardiac marker POC detection-based prod-
ucts launched in the past three years include Cardio 
3 (Alere International, Waltham, MA), a triple-
analyte test for troponin I, BNP, and CK-MB 
(creatinine kinase MB). 
Blood testing has seen several recent POC ad-
vances.  Verax Biomedical (Worcester, MA; 
www.verax.biomedical.com) developed the platelet 
PGD test to address bacterial contamination of red 
blood cells: a pre-prepared platelet sample is ap-
plied to the plastic chip with a colored line appear-
ing in the presence of Gram-positive or Gram-
negative bacteria.  Instrumentation Laboratory 
(Bedford, MA) received FDA approval in 2011 for 
infant bilirubin (tBili) testing, an immunoassay per-
formed on their GEM Premier 4000 critical care 
analyzer.  The ABORhCard® (Micronics, Seattle, 
WA; www.micronics.net) contains anti-A, anti-B, 
and anti-D antibodies in its microfluidic channels 
for blood type (A/B/O and Rh factor) determination 
upon blood sample application. 
Rapid diagnostics for monitoring protein levels, 
enzymatic activities and modifications of mito-
chondrial proteins in mitochondrial disease have 
been reported by Marusich et al.274  This device has 
a lateral flow dipstick immunoassay format with 
four spatially separated 2-site immunocapture as-
says, with one monoclonal antibody (MAb) specific 
for the target protein on the capture zone, while the 
second labeled MAb specific for a different epitope 
on the same protein is introduced with the sample., 
Unlike mass spectrometry, this approach can be 
adapted into functional POC tests in the characteri-
zation and diagnosis of disease. 
A microfluidic electrochemical immunoassay 
for urinary hippuric acid (HA) was integrated with a 
PDMS chip attached to a glass substrate with pat-
terned electrodes.275  The chip contains a chamber 
to store antibodies that bind to HA antigens.  Un-
bound antigens enter the reaction chamber, resulting 
in a redox reaction on the electrode surface that cor-
relates with the concentration of HA.275  Another 
novel microfluidic format includes the development 
of a portable disc-based fully automated ELISA 
based on colorimetric detection through integrated 
photodiodes and LEDs for infectious disease detec-
tion.125 
 
Protein Expression and Purification.  To char-
acterize specific gene products, it is necessary to 
express and purify recombinant proteins in a variety 
of expression hosts quickly and efficiently.  Such 
recombinant proteins are then required for the pro-
duction of antibodies, development of functional 
assays, identification of interacting proteins, and 
characterization of their native structures.  The need 
for fast and efficient preparation of active proteins 
and the relevant determination of the optimal condi-
tions for expression and purification of recombinant 
proteins is mainly fueled by the pharmaceutical in-
dustry, but progress in this area is beneficial to POC 
test development.  A POC device for quantification 
of recombinant proteins was described by Enomoto 
et al.276  They reported a novel double-epitope tag 
approach, composed of 19 amino acids, that pro-
vides a rapid method to detect recombinant proteins 
via homogeneous sandwich immunoassay.  
 
Nucleic acids 
 Nucleic acid assays are the fastest growing 
component of biomedical diagnostics, replacing or 
complementing culture-based, biochemical, and 
immunological assays in microbiology laboratories 
and, very recently, at the point of care.  Detection of 
viruses and other pathogenic microorganisms, muta-
tions causing human genetic disorders, cancer, hy-
pertension and other lifestyle-related diseases 
widely rely upon genetic testing.  In this section we 
present advances in amplification (replication) of 
nucleic acid targets, the synthetic nucleic acids 
known as aptamers, and two rapidly growing appli-
cation areas: infectious diseases and food safety. 
The most commonly used technique for gene 
amplification—necessary in many cases to keep 
sample sizes reasonable and to reduce the complex-
ity of the analytical task—is PCR with optical de-
tection.  The PCR process is complex, requiring a 
thermal cycler for the reaction; if multiple targets 
are to be detected in one reaction, electrophoresis 
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and fluorescent labeling separates the amplification 
products and renders them detectable.  Only a few 
years ago, this combination of techniques appeared 
inappropriate for applications requiring a small 
footprint and ease of use, but significant effort has 
been invested in the development of compact, cost-
effective methods to detect nucleic acids. 
A recent report on real-time PCR assays for in-
fluenza A and B viruses describes the determination 
of type (A or B) and subtype (H1, H3, or H5) using 
a single-step/single-reaction vessel format.277  Ar-
chived reference strains were compared to uncul-
tured primary clinical samples (throat swab/nasal 
wash).  The A- and B-specific assays detected all 16 
influenza type-A viruses and both currently circulat-
ing influenza type-B lineages (Yamagata and Victo-
ria).  The assay has a detection threshold of ap-
proximately 100 target molecules.  These assays are 
said to be appropriate for field deployment for POC 
screening during a pandemic influenza outbreak. 
An application of a quadruple-allele dipstick as-
say for the simultaneous visual genotyping of the 
two key components of the innate immune system, 
responsible for initiating an inflammatory response 
against microbial pathogens, was recently presented 
by Litos et al.278  The method involves PCR ampli-
fication of the region spanning the two polymorphic 
sites, followed by a single primer-extension reaction 
for all four alleles, requiring only minutes. 
Tomita et al.279 employed an alternative ampli-
fication method to classical PCR.  Their detection 
system, using loop-mediated isothermal amplifica-
tion (LAMP), allows for visualization of substantial 
alteration of the fluorescence during the one-step 
amplification reaction, requiring some 30 – 60 min.  
Another sensitive amplification technique, isother-
mal rolling circle amplification (RCA), was re-
ported by Stougaard et al. to provide single-
molecule detection and quantitative results.  RCA 
has enabled the detection of biomarkers at the aM 
concentration level.280 
In DNA microarrays, optical methods based on 
fluorescence detection are the standard for quantify-
ing hybridization between surface-immobilized 
probes and fluorophore-labeled analytical targets.  
Electrochemical detection techniques are emerging 
that can replace physically bulky optical instrumen-
tation in support of portable devices for POC appli-
cations.  Defever et al.281 described proof-of-
principle real-time PCR using cyclic voltammetry to 
indirectly monitor the amplified DNA product gen-
erated in the PCR reaction solution after each PCR 
cycle.  The design requires the addition of only a 
minute amount of redox catalyst to the PCR mix-
ture; rapid detection is claimed despite poorer sensi-
tivity than optically based real-time PCR (the expo-
nential amplification provided by PCR can often 
compensate for limitations in sensitivity).  An elec-
trochemical DNA microarray system has been 
available for several years from Combimatrix 
(http://www.combimatrix.com/). 
Multiplexed and specific detection of ferrocene-
conjugated DNA targets, as well as real-time moni-
toring of hybridization on an active electrochemical 
biosensor array, was reported by Levine et al.282  
This approach, based on fully integrated standard 
complementary metal-oxide-semiconductor 
(CMOS) technology, is a potential basis for portable 
DNA diagnostic platforms. 
An interesting overview of the technologies of 
colorimetric biosensors based on DNA-nanoparticle 
(NP) aggregation assays was presented by Sato et 
al.283  The authors compared two types of DNA-NP 
aggregation assays: aggregometry based on the 
crosslinking of gold NPs, and a more novel non-
crosslinking system. 
 
 Aptamers.  Aptamers, a synthetic alternative to 
biologically-derived antibodies, are single-stranded 
oligonucleotides that can be DNA or RNA, or can 
be peptide-based; they are synthesized in a combi-
natorial variety of base sequences, then screened to 
discover those that bind specifically to target mole-
cules.11  Aptamers have desirable properties includ-
ing increased stability (relative to many antibodies), 
ease of production (relative to biological production 
of antibodies), ease of manipulation, and ease of 
modification.242, 268  The application of aptamers to 
biosensors was recently reviewed in depth by Iliuk 
et al.269 
Cass and Zhang describe how the access of a so-
lution-phase redox species, or the impedance at an 
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electrode, is modulated by the binding of a target 
nucleic acid oligomer to an immobilized selective 
capture aptamer to produce an analytical signal.271  
Similar strategies were used to detect platelet-
derived growth factor284 and thrombin285 using ap-
tamer probes.  The electrochemical detection of 
bacteria using carbon nanotubes coated with aptam-
ers has also been reported.286 
Optical biosensors are appropriate for use in 
conjunction with aptamers, which are easily labeled 
with fluorophores and chromophores.  Xu et al.242 
presented aptamer-functionalized gold nanoparticles 
in a dry reagent lateral flow biosensor for thrombin 
analysis, with excellent selectivity due to the lack of 
interference from casein, IgG, or IgM, which often 
interfere with antibody-based assays. 
Novel optical biosensor platforms using near-
infrared fluorescent single-walled carbon nanotubes 
(SWNTs), functionalized with aptamer DNA for the 
real-time detection of cell-signaling molecules, such 
as insulin released from pancreatic cells, have been 
reported (Figure 9).287 
 
Infectious Diseases and Food/Water safety.  
New and reemerging infectious diseases, including 
pandemic viruses and drug-resistant bacteria, repre-
sent serious health and global security threats: more 
than 25% of 57 million annual deaths worldwide are 
related directly to infectious diseases (see Figure 
10), not including the millions of deaths due to past 
infections.288  Toxicity and infections caused by 
food-borne pathogens also represent an increasing 
public health problem, and diagnostic tests in multi-
plex format are needed for the rapid identification 
of food contamination caused by such microbial 
species as Escherichia coli O157:H7, Listeria 
monocytogenes and Salmonella spp. (40,000 
cases/year in the United States alone).289 
Most state-of-art diagnostic devices suitable for 
pathogens rely on PCR-based procedures.290  They 
are typically sensitive and accurate; in particular, 
real-time PCR (qPCR), in addition to being an 
automated high-throughput-compatible technique, 
allows quantification of foodborne pathogens.291  
Other promising pathogen-detection techniques in-
clude an isothermal target-and-probe amplification 
method based on a combination of isothermal chain 
amplification and FRET cycling probe 
technology,289 as well as automated DEP-facilitated 
image analysis292 that targets single-cell LODs. 
 
Blood Chemistry 
The principles of the i-STAT device, an electro-
chemically-based POC blood chemistry analyzer 
with cartridges consumed by the millions each year, 
have been described by Lauks30 and in the patent 
literature.293  It features an electrochemical cell in a 
microchannel, with buffer and reagent pouch and 
diaphragm pump, operated by a plunger incorpo-
rated in the reader.  Air bubbles separate reagents, 
sample, and wash solutions.  An enzyme label (e.g. 
alkaline phosphatase) converts an electrochemi-
cally-inactive substrate (e.g. p-aminophenol phos-
phate) to an electrochemically active one (e.g. p-
aminophenol).  An interesting aspect of the design, 
not discussed in the literature, is the use of convec-
tive effects in the meniscus of a moving fluid to 
 
Figure 9.  Optical nanosensor for insulin meas-
urement from pancreatic cells.  SWNTs are func-
tionalized with insulin-binding aptamer DNA to 
recognize target insulin, which is optically detected 
in the near IR via quenching.  (Reprinted with per-
mission from Cha et al.287) 
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promote mixing and dispersion of reagents dried 
into the channel.  A recent description in the patent 
literature reveals significant improvements in de-
vice design: Lowe et al.294 describe a system in 
which a step in a fluidic channel is used to form an 
interface between a whole blood sample and a 
buffer, stored in a pouch on the test cartridge.  Anti-
body-sensitized magnetic beads, dried onto the 
walls of the inlet channel, are incubated with the 
sample by agitation using a motor-driven magnet.  
After the incubation period, the beads are drawn 
into the buffer, further washed by agitation and then 
moved to the detection zone.  An electrochemical 
scheme using horseradish peroxidase, coupled to 
the oxidation of glucose, acts as amplifier and sig-
nal generator. 
 
Coagulation markers  
Coagulation testing has joined the leaders in 
POC testing due to the well-defined need for anti-
coagulation monitoring295 after such common pro-
cedures as hip surgery.  Devices include clot-based 
assays that measure the physical clotting time of 
blood and clotting-factor assays that allow for more 
accurate diagnoses of clotting factor deficiencies 
using immunoassay. 
Conventional clot-based assays have been on 
the market for many years, including prothrombin 
(PT), activated partial thromboplastin time (aPTT), 
activated clotting time (ACT), and thrombin clot-
ting time (TCT) assays, and have been reviewed in 
detail.18, 296  The most common commercial coagu-
lation POC format is the HemoSense INRatio sys-
tem (HemoSense Inc., USA) for PT/INR home-
testing, which uses electrochemical impedance to 
measure the onset of clotting via the interaction of a 
blood sample with a PT activator.295  One of the 
cartridges for the i-STAT analyzer measures 
PT/INR amperometrically: thrombin generated dur-
ing clotting cleaves an electrochemical substrate.  
Many POC coagulation devices use mechanical or 
optical detection or a combination of both such as 
the Hemochron Signature (ITC, USA), GEM® PCL 
Plus system (Instrumentation Laboratory) or the 
Thrombotrack™ Solo (Axis-Shield).  These sys-
tems can execute a range of clot-based tests using 
the appropriate clotting reagent (PT/aPTT/TT) and 
measuring such parameters as the physical changes 
that occur during clot formation, or the increasing 
occlusion of light as clotting progresses.296a 
Hereditary thrombotic disorders resulting in 
clotting factor deficiencies cannot be detected using 
conventional clot-based tests, which has led to the 
development of more specific factor assays, now 
trending towards immunoassays.  Assay targets in-
clude D-dimers and fibrinogen degradation products 
(FDPs), with increasing interest in developing POC 
devices that target coagulation markers such as pro-
tein C, protein S, antithrombin, and factor V Leidin.  
Numerous POC devices for measuring D-dimer ex-
ist on the market.  The CARDIAC D-dimer assay 
from Roche Diagnostics (Indianapolis, IN) is a 
quantitative POC device where two D-dimer recog-
nition antibodies form a sandwich complex with the 
D-dimer, which is taken up by a streptavidin line in 
the detection zone via the biotinylated antibody.  
This gold-labeled antibody results in a color change 
and a red signal line is quantitatively recorded by 
the reader.297 
 
Figure 10.  More than 25% of total annual deaths 
are caused by infectious diseases, with respiratory 
infections and HIV/AIDS being responsible for the 
majority of the deaths. (Published by the World 
Health Organization and reprinted with permission 
from Morens et. al.288) 
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The SimpliRED® D-dimer assay from BB In-
ternational (Cardiff, UK) is a whole-blood aggluti-
nation assay where the on-chip reagent causes the 
red blood cells to visibly coalesce (www.d-
dimer.co.uk).  Immunoturbidimetry is used in the 
MiniQuant® D-dimer assay from Kordia (Leiden, 
The Netherlands; www.kordia.nl), in which anti-
body particles agglutinate, increase turbidity, and 
cause changes in light scattering.  The AQT90 Flex 
D-dimer assay from Radiometer (Brønshøj, Den-
mark; www.radiometer.com) uses time-resolved 
fluorescence detection.298 
In the laboratory, whole-blood aggregometry is 
considered the gold standard for platelet function 
testing.  POC devices that assess platelet function 
have been reviewed extensively.296a, b, 299  Two 
commonly used POC platelet function assays in-
clude the PFA-100 (Siemens Medical Solutions, 
Malvern, PA), which uses shear to induce platelet 
adhesion, activation, and aggregation,296b while the 
Plateletworks device from Helena Laboratories 
(Beaumont, TX) uses an impedance-based cell 
counter.296a, 300  Thromboelastography (TEG), a 
global test of hemostasis, generates information 
about clot strength and stability.301  TEG is now be-
ing adapted for mapping platelets through platelet 
inhibition and activation, as with the TEG® Platelet 
Mapping System™ from Hemoscope Corporation 
(Niles, IL).296a, 300 
In the research arena, a rapid POC device for 
measuring plasma fibrinogen concentration based 
on a single-use lateral flow microfluidic chip has 
been developed.158  As a plasma sample comes into 
contact with a thrombin-coated polymeric micro-
structured LFA device, flow is arrested and the dis-
tance traveled  by the sample can be correlated with 
fibrinogen concentration.  
An immunosensor for the detection of FDPs us-
ing quartz crystal microbalance technology com-
bined with latex agglutination was reported by Ai-
zawa.302  Thuerlemann et al.229 have developed an 
amperometric test strip for the detection of throm-
bin, whereby cleavage of the substrate is detected 
electrochemically.  This approach could be used for 
factor V Leidin and activated protein C resistance 
screening in plasma and whole blood samples.  
More recently, an aptamer-based polymer microflu-
idic device for measuring thrombin was developed 
incorporating the use of magnetic beads and quan-
tum dots.303 
 
Whole cells  
Cell-based analyses implemented in miniatur-
ized devices suitable for POC application now 
range from red and white blood cell counts to plate-
let function and platelet-protein interaction assays in 
whole blood.  VanBerkel et al. recently reported a 
microfluidic device for three-part differential leuko-
cyte count (granulocyte/lymphocyte/monocyte) plus 
erythrocyte (red cell) and thrombocyte (platelet) 
counts in human blood; data were corroborated with 
clinical laboratory analyses.304  Neutrophil (the 
most abundant white cell) migration is a key phe-
nomenon in the immune response to bacterial infec-
tion, and assays have been developed using less 
than 10 !L of whole blood to perform chemotaxis 
under the influence of competing chemokines.305 
Platelet function is critical to hemostasis, and 
platelets are implicated in everything from 
cardiovascular disease to the hematogenous spread 
of cancer.  Platelet function analysis, including POC 
methods, was surveyed in 2005,299d and platelet 
function is now assayed clinically using the com-
mercial VerifyNow POC system,306 which infers 
function from platelet aggregation measurements.  
A sufficient volume of clinical results has been 
amassed for concerns over limitations of this ap-
proach to be expressed.299c 
The microfluidic means to directly assess plate-
let function in whole blood via dynamic interactions 
with immobilized proteins under conditions of arte-
rial shear flow have been reported recently.307  
Platelet activation statistics have been assayed (and 
correlated with antiplatelet drug effects) from their 
binding occupancy on arrays of platelet-sized sur-
face spots of proteins and antibodies.53 
Counting T lymphocytes (particularly CD4+, in 
some cases supplemented by CD3+ or CD8+, cells) 
is an effective means to stage and monitor HIV-
infected patients.308  A label-free POC-appropriate 
CD4-cell-counting device using microfluidics309 
aims to keep costs low enough for developing world 
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applications.  Integration of semiconductor quantum 
dots into nano-biochip systems for enumeration of 
CD4+ T-cell counts in a POC-type device has been 
reported as well.160 
Assaying the small numbers of circulating tu-
mor cells (CTCs)—sometimes just a few per mL of 
blood—that are present in early stages of metastasis 
or cancer recurrence is particularly challenging.  
Although point-of-care measurement is not prereq-
uisite for such assays, microfluidic technologies are 
nonetheless being applied to this needle-in-a-
haystack problem, with limited preliminary success.  
Aptamers have been used for capture and gold 
nanoparticles for labeling to detect cancer cells in 
just 15 min,310 although a minimum of 800 cancer 
cells must be captured for detection.  Arrays of 
crescent-shaped capture structures were employed 
to isolate CTCs from blood, at a very realistic cell 
density of 1 – 3 CTCs/mL, with impressive capture 
efficiencies for three cancer cell types.311 
The use of microfluidics for cell separations of 
all sorts was recently reviewed.152  In a recent appli-
cation of so-called digital microfluidics, a droplet-
based device was used to isolate human T lym-
phoma cells.166  A diagnostic device for bovine 
mastitis was demonstrated using a compact-disc-
format centrifugal platform to separate white cells 
from whole milk samples by centrifugal sedimenta-
tion.312 
 
 
TRENDS, UNMET NEEDS, PERSPECTIVES 
Glucose   
The trends in glucose POC devices are towards 
higher accuracy and minimally- or non-invasive de-
vices directed at continuous monitoring.  Advances 
in electrochemical device technology and the tech-
nology for protective membranes have been signifi-
cant.66b  Non-invasive measurement has progressed 
based on advances using infra-red or Raman313  
spectroscopy.  Whilst it is relatively simple to 
measure a non-invasive signal that correlates with 
in-vivo glucose concentrations, it is considerably 
more difficult to construct glucose calibration mod-
els that prospectively provide accurate glucose con-
centrations in human subjects:314 calibration re-
quires a significant number of invasive measure-
ments covering a range of glucose concentrations 
and needs to account for many confounding vari-
ables.  Caduff et al. demonstrated some success us-
ing non-specific measurements of dielectric re-
sponse in three frequency ranges (kHz – GHz) and 
optical reflectance at three different wavelengths.315  
Progress has been significant towards autonomous 
closed-loop control of insulin levels—effectively, 
an artificial pancreas combining continuous glucose 
sensing with an insulin pump—and a system from 
Medtronic is undergoing testing, but challenges re-
main.316 
 
Global Health and the Developing World 
The development of POC diagnostic devices for 
limited-resource settings, including the developing 
world, is a very active area52b, 112, 317 due to the re-
markable need and substantial funding from public 
and private sources: the U.S. Global Health Initia-
tive; the Bill & Melinda Gates Foundation (Seattle); 
the Program for Appropriate Technology in Health 
(PATH; Seattle); the UK Department for Interna-
tional Development; the Foundation for Innovative 
New Diagnostics (FIND; Geneva); and the Euro-
pean Union’s Seventh Framework Programme 
(FP7) are some of the major initiatives.  Infectious 
diseases have attracted particular attention and ac-
tivity in the context of global health POC diagnos-
tics, including HIV, tuberculosis (TB), and malaria. 
The current status318 and emerging issues319 
relevant to tackling HIV through robust diagnostics 
in the developing world have been reviewed.  The 
status of research and barriers for development of 
point-of-care tests for infectious diseases prevalent 
in developing countries317c, 320 and particularly for 
active TB have been reviewed.55  Studies of the an-
tigens used for TB diagnosis have been analyzed,321 
with a conclusion that POC tests are urgently 
needed, particularly where TB is endemic.  To do 
this, a number of very specific challenges must be 
overcome: robustness, storage, cost, and ease-of-
use.  The context in which the diagnostics must op-
erate, appropriate diagnostic technologies already in 
distribution, opportunities for innovation, adaptation 
and cost reduction, along with some emerging tech-
Page 33 of 62
ACS Paragon Plus Environment
Analytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
nologies that promise to address this challenge, 
have been reviewed.317b  One issue, highlighted by 
Peeling and Mabey, is that sub-standard tests have 
undermined confidence in the use of POC devices; 
they conclude that appropriate systems for quality 
control of POC tests needs to be developed if they 
are to achieve their maximum potential.322  In this 
context, system design is clearly important, and one 
principle is, arguably, that people are more reliable 
than machines in limited-resource environments: 
the operation of this idea can be seen in the system 
presented by Chin et al.,323 which used silver en-
hancement of captured gold colloid-labeled antibod-
ies, where the device itself is very simple – no more 
than a set of channels carrying antigen characteristic 
of specific diseases (HIV  and other sexually trans-
mitted diseases), and a simple optical reader – but 
the flow control is done with a hand-operated sy-
ringe.  Reagents (which hence define specific as-
pects of the technique) are chosen for their stability, 
are stored separately from the chip, and flow se-
quentially through the chip separated by air bubbles. 
Stimulated in part by a drive to overcome issues 
of cost and to improve performance of simple de-
vices designed for use in limited-resource econo-
mies, there has been much recent work on assay 
configurations that use inexpensive substrates and 
readily available reader devices such as camera 
phones.  Breslauer et al. describe mobile phone-
based clinical microscopy.324  Weigl et al. have re-
viewed progress toward development of disposable, 
low-cost, easy-to-use microfluidics-based diagnos-
tics that require no instrument at all.  They present 
examples of microfluidic functional elements—
including mixers, separators, and detectors, as well 
as complete microfluidic devices—that function 
entirely without any moving parts or external power 
sources.112  In a similar vein, a lab-on-a-tube (LOT) 
device for POC measurement of multiple analytes 
was described.218b  It uses passive capillary force or 
active suction to avoid the need for a pump or injec-
tion components, making it in some sense a micro-
fabricated implementation of the passive LFA ap-
proach.  Evolving low-cost technologies for the 
control and measurement electronics associated 
with POC devices is quite relevant.325 
Paper, one of the original substrates conceived 
for lateral flow assays but subsequently displaced 
by porous nitrocellulose on account of the control 
that this material offers over flow and protein ad-
sorption,326 has experienced a resurgence of interest 
in academic research.327  Patterning is easily 
achieved by impregnating the paper with a hydro-
phobic material, by printing,327f and hence structures 
for precise control of the flow can be realized.328  
One of the central questions in bioactive paper de-
velopment is the impact of the properties of the cel-
lulosic support on both immobilization and func-
tionality of biomolecules.  A recent review on inkjet 
printing of biomolecules for bioactive paper appli-
cations reports progress made in understanding fac-
tors that affect the activity of biomolecules physi-
cally immobilized on cellulosic supports.329  Paper-
based microfluidic devices have been combined 
with optical detection using a mobile phone camera 
for telemedicine.317a  The use of multiple colorimet-
ric indicators to extend dynamic range has been re-
ported.330  Channel networks can be set up to enable 
the automated sequential delivery of multiple rea-
gents to a detection region with a single user-
activation step, for example to implement signal 
enhancement with comparable ease of use to con-
ventional lateral flow tests.331  96- and 384-
microzone plates fabricated in paper as alternatives 
to conventional multi-well plates fabricated in 
molded polymers have been illustrated; quantitative 
colorimetric correlation using a scanner or camera 
to image the zones has been demonstrated.332  Elec-
trochemical detection and measurement on paper-
based devices, using simple apparatus similar to the 
reader for a commercial glucose device, has also 
been demonstrated as an alternative low-cost tech-
nology.218a, 333  Impedance measurements in fluidic 
devices have been implemented using a portable 
music player and a laptop soundcard.334 
Thread has been explored as a means for low-
cost device construction,149a, 335 with fluid moving 
through the thread by capillary action.  Networks 
can be constructed by weaving, and if the thread is 
sewn through a hydrophobic material, complex flu-
idic structures can be constructed and devices in-
corporated into bandages, for example.  Colorimet-
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ric assays have been demonstrated on thread-based 
devices to detect ketones, nitrite, protein, glucose in 
artificial urine, and alkaline phosphatase in artificial 
plasma.149a  "Switches" that control when or where 
flow can occur, or allow the mixing of multiple flu-
ids, have been successfully prototyped from multi-
filament threads, plastic films, and household adhe-
sive.335b 
 
Personalized Medicine and Home Testing  
Personalized medicine tailors healthcare to indi-
viduals, using their genotypic and phenotypic de-
tails to complement generic guidelines derived from 
large-cohort studies, e.g., for choices of medication 
and dosage.  Driving this trend are the potential for 
better healthcare for the patient at lower cost, along 
with the salvaging of thousands of orphan drugs that 
are safe and effective only for some of the popula-
tion, who can typically be identified by genotyping.  
For some drugs, personalization may be as simple 
as adjusting the dosage to a patient’s own metabo-
lism as well as current physiological status: home 
POC measurement of clotting time, for example, 
keeps a patient’s anticoagulant level in the impor-
tant window between spontaneous internal clotting 
and a dangerous propensity to bleed.  Huckle con-
cludes that anticoagulant therapy monitoring is now 
joining diabetes and pregnancy as a significant POC 
success.336 
Antiplatelet drugs, including aspirin and Plavix, 
are intended to diminish the risk of vascular occlu-
sion.  These agents are not uniformly effective for 
all patients and efficacy may vary with a patient’s 
health status, suggesting a role for POC platelet 
function testing to personalize dosage or choice of 
drug.307, 337 
Selected infectious disease testing could save 
time and money through POC home testing.  The 
home market for POC HIV,338 chlamydia, and other 
STD tests is significant and growing.  Streptococcal 
pharyngitis (“strep throat”) home diagnosis in chil-
dren would save many doctor visits, as would reli-
able differentiation between rhinoviral and upper 
respiratory bacterial infection, an important ancil-
lary benefit being to diminish untold numbers of 
prescriptions for antibiotics, written inappropriately 
and usually under patient-exerted duress, for a 
common cold with no proven bacterial component.  
This practice currently causes problematic antibiotic 
resistance. 
As the average population of the developed 
world ages, healthcare and well being will increase 
their economic and social importance.  Significant 
markets for home testing could emerge for every-
thing from cardiovascular health to osteoporosis to 
a range of nutritional deficiencies, once the right 
combinations of biomarkers and affordable tech-
nologies are developed. 
 
Technology Trends  
Low-cost polymer substrates, paper and thread 
microfluidics, and low-cost readers using smart 
phones were discussed above.  Digital/droplet mi-
crofluidic devices are actively researched and just 
beginning to reach the POC.  The line between “tra-
ditional” (e.g., porous nitrocellulose) lateral flow 
assay devices and microfluidic platforms is blur-
ring; in most cases, clever design of the platform 
will result, for high-volume manufacture, in the on-
board reagents and packaging costing more than the 
fluidic consumable. 
While PCR remains a workhorse for nucleic 
acid amplification, the trend in diagnostics research 
is to consider a range of related techniques as well, 
including RCA, LAMP, NASBA, MDA, TMA, 
SDA, and LCA (rolling-circle amplification, loop-
mediated isothermal amplification, nucleic acid se-
quence-based amplification, multiple-displacement 
amplification, transcription-mediated amplification, 
strand-displacement amplification, and ligase chain 
reaction, respectively), as well as cleavase In-
vader™.  Importantly, many of these methods are 
isothermal and operate at lower temperatures than 
PCR, making their integration with microfluidic 
technologies more straightforward. 
In detection, new optical methods exploit phe-
nomena including up-conversion, high-brightness 
nanoparticles, total-internal-reflection fluorescence 
(TIRF), SAF, FRET, and a range of plasmon-based 
effects.  In many cases, nanoparticles are the re-
porter for optical detection.  The above technologies 
enhance signal, reduce background, or both; com-
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bined with low-cost, compact high-intensity solid-
state light sources, this drives POC LODs ever 
lower.  The trend now is for either nonspecific re-
sponse or limitations of antibody-antigen binding 
affinity to determine the LOD, rather than the per-
formance of the detection system. 
The significant trend in selective recognition is 
the use of aptamers in place of antibodies for the 
specific binding of proteins.  This replaces highly 
complex biomolecules produced by living organ-
isms and often varying from batch to batch and 
vendor to vendor, with synthetically-generated rea-
gents. 
A number of POC-suitable applications of 
nanobiotechnology are surveyed by Jain.339  
Nanotechnology for membranes, filters and sieves 
has been reviewed as well.110  
 
Multiplexing.  Detecting multiple analytes in a 
single POC test is an important trend: many of the 
most promising new POC opportunities are in 
multi-analyte tests or panels, including cancer 
markers, cardiac health, and infectious disease.  
Testing for infection-causing pathogens in a blood 
sample is a particularly important future POC appli-
cation: it could replace laboratory culture-based 
analysis requiring hours to days for organism 
growth, the results of which sometimes arrive too 
late for a patient with a bloodstream infection that 
leads to septic shock and death.  To identify the 
causative pathogen and thus select the proper anti-
biotic, genetically specific testing for ~ 8 – 30 dif-
ferent microbial strains should provide identifica-
tion for 80 – 90% of all serious infections.  Quan-
tum-dot barcodes are one approach that has been 
studied for multiplexed infectious disease diagnos-
tics.340 
Sexually transmitted infectious diseases are a 
challenge in both low-resource and developed envi-
ronments.  A single POC device that includes the 
commonest of the STDs will save time and money, 
and rapid results can help reduce the spread of 
STDs by ensuring that patients learn their status and 
how to treat it before leaving the clinic or hospital. 
Monitoring cancer treatment efficacy or check-
ing for recurrence usually requires tracking multiple 
biomarkers.  The determination of cancer markers 
in serum and saliva using quantum dot bioconjugate 
labels has been reported.234  A fluorophore-based 
bio-barcode amplification protein assay has been 
researched,225 and multi-antigen fluorescence 
immunoassays also have been demonstrated using a 
microfluidic device to provide 100 separate assay 
chambers.341 
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